


The secreted rHSA was isolated as follows. The growth medium was centrifuged to harvest the culture supernatant, which was brought to 50% saturation by the addition of solid ammonium sulfate with stirring at room temperature. The mixture was then incubated at 4 °C for 1 h. The resulting precipitate was removed by centrifugation, and the supernatant fluid was brought to 95% saturation with ammonium sulfate. The precipitated protein, which contains rHSA, was collected by centrifugation and dissolved in distilled water. The brownish solution was dialyzed for 48 h at 4 °C against 100 volumes of distilled water, followed by 24 h against 100 volumes of 50 mM potassium phosphated buffer (pH 7.0). The dialysate was then loaded onto a Cibacron Blue column of Blue Sepharose 6 Fast Flow (Amersham Pharmacia Biotech) and washed with 10 bed volumes of 50 mM potassium phosphate. Elution of the rHSA(mutant) was carried out with 3 M NaCl and the eluent dialyzed against 50 mM potassium phosphate. After concentration using an ADVANTEC Q0100 ultrafilter (10 kDa Mw cutoff) in an UHP-43K ultraholder, the samples were applied to a Superdex 75 column (Amersham Pharmacia Biotech) using 50 mM potassium phosphate as the running buffer. All the purification steps were followed by SDS-PAGE analysis. Each rHSA(mutant) exhibited a single band and migrated the same distance as rHSA(wt). The protein concentration was assayed by measuring the absorbance at 280 nm ( $\epsilon_{280} = 3.4 \times 10^4 \text{ M}^{-1} \text{ cm}^{-1}$ ).

**Preparations of rHSA-Hemin and rHSA-Heme Complexes.** The ferric rHSA(mutant)-hemin complexes were prepared according to our previously reported procedures for rHSA(wt)-hemin.<sup>3e</sup> Typically 5 mL of 0.1 mM rHSA(mutant) in 50 mM potassium phosphate (pH 7.0) was mixed with 0.8 mL of 0.688 mM hemin in DMSO [hemin:rHSA-(mutant) molar ratio of 1.1] and incubated overnight with rotation in the dark at room temperature. The complex was then diluted with 50 mM potassium phosphate (200 mL) and concentrated to the initial volume (5.8 mL) using an ADVANTEC Q0100 ultrafilter (10 kDa Mw cutoff). These dilution and concentration cycles were repeated to reduce the final concentration of DMSO to <0.1 vol %. The resulting samples were analyzed by a SDS-PAGE to confirm the protein integrity and concentration.

The 50 mM phosphate-buffered solution (pH 7.0) of rHSA(mutant)-hemin ([hemin] = ca. 10  $\mu\text{M}$ ) in a 10 mm path length optical quartz cuvette sealed with a rubber septum was purged with Ar for 40 min. A small excess amount of degassed aqueous sodium dithionite was added by microsyringe to the sample under an Ar atmosphere to reduce the central ferric ion of the hemin, generating the deoxy ferrous rHSA-(mutant)-heme complexes.

**Kinetic Measurements for O<sub>2</sub> and CO Bindings.** Kinetics studies were carried out using laser flash photolysis techniques at 22 °C, except for the determination of the CO dissociation rates. Laser flash photolysis experiments were performed using a Unisoku TSP-1000WK time-resolved spectrophotometer with a Spectron Laser Systems SL803G-10 Q-switched Nd:YAG laser, which generated a second-harmonic (532 nm) pulse of 6 ns duration (10 Hz). The probe light from a 150 W xenon arc-lamp was passed through an UV cutoff filter and an Asahi Spectra MC filter before irradiation to minimize any sample damage. Normally, fresh solutions of the deoxy rHSA(mutant)-heme were made up for each set of experiments, and the gas mixture with the desired partial pressure of O<sub>2</sub>/CO/N<sub>2</sub> prepared by a KOFLOC Gasblender GB-3C was flowed into the sample cuvette for 20 min for equilibration.

In general, recombination following laser flash photolysis to hemeO<sub>2</sub> or hemeCO occurs according to eq 1 with the association rate constant ( $k_{\text{on}}^{\text{L}}$ ), dissociation rate constant ( $k_{\text{off}}^{\text{L}}$ ), and apparent rate constant ( $k_{\text{app}}$ ) given by eq 2.<sup>14,15</sup> The values of  $k_{\text{app}}$  were obtained directly from the log plots of the change in absorbance ( $\Delta A$ ) versus time. The gas




$$k_{\text{app}} = k_{\text{on}}^{\text{L}}[\text{L}] + k_{\text{off}}^{\text{L}} \quad (2)$$

concentrations were always higher than that of the heme; therefore, the pseudo-first-order approximation can be applied throughout. For CO rebinding at high [CO], eq 2 reduces to eq 3 because  $k_{\text{on}}^{\text{CO}}[\text{CO}] \gg k_{\text{off}}^{\text{CO}}$ .

$$k_{\text{app}} \approx k_{\text{on}}^{\text{CO}}[\text{CO}] \quad (3)$$

Thus,  $k_{\text{on}}^{\text{CO}}$  of the rHSA(mutant)-heme was easily calculated from  $k_{\text{app}}/[\text{CO}]$ .

The O<sub>2</sub> association rates ( $k_{\text{on}}^{\text{O}_2}$ ) and the O<sub>2</sub> binding constants [ $K^{\text{O}_2} = (P_{1/2}^{\text{O}_2})^{-1}$ ] of the rHSA(mutant)-heme were measured using the competitive rebinding technique.<sup>14,15</sup> Photolysis of hemeCO in the presence of CO and O<sub>2</sub> gives the five-*N*-coordinate heme (deoxy state), which is first trapped as hemeO<sub>2</sub> and subsequently converted back to hemeCO (eq 4).



The CO concentration was held constant, and the fast and slow kinetics were measured at different [O<sub>2</sub>]. The fast process is given by eq 5, allowing the direct determination of  $k_{\text{on}}^{\text{O}_2}$  from a plot of  $k_{\text{app}}(\text{fast})$  versus [O<sub>2</sub>].

$$k_{\text{app}}(\text{fast}) = k_{\text{on}}^{\text{O}_2}[\text{O}_2] + k_{\text{off}}^{\text{O}_2} + k_{\text{on}}^{\text{CO}}[\text{CO}] \quad (5)$$

The rate constant for the slower process,  $k_{\text{app}}(\text{slow})$ , is substituted into Traylor's eq 6 to obtain  $K^{\text{O}_2} [(P_{1/2}^{\text{O}_2})^{-1}]$ .<sup>15</sup>

$$\frac{k_{\text{on}}^{\text{CO}}[\text{CO}]}{k_{\text{app}}(\text{slow})} = K^{\text{O}_2}[\text{O}_2] + \frac{k_{\text{on}}^{\text{CO}}[\text{CO}]}{k_{\text{off}}^{\text{O}_2}} + 1 \quad (6)$$

The value of  $k_{\text{on}}^{\text{CO}}[\text{CO}]$  is constant; therefore, the plots of  $k_{\text{on}}^{\text{CO}}[\text{CO}]/k_{\text{app}}(\text{slow})$  versus [O<sub>2</sub>] affords  $K^{\text{O}_2}$ .

The relaxation curves that accompanied the O<sub>2</sub> or CO recombination were fitted to single- or double-exponentials using the Unisoku Spectroscopy & Kinetics Software. The  $k_{\text{off}}^{\text{O}_2}$  values can be determined from the y-intercept of eq 5 or 6, but they often have large deviations. Therefore, we calculated  $k_{\text{off}}^{\text{O}_2}$  from  $k_{\text{on}}^{\text{O}_2}/K^{\text{O}_2}$  (both obtained from slopes).


The CO dissociation from the rHSA(mutant)-hemeCO was measured by carrying out the replacement reaction with NO.<sup>16</sup> A Sephadex G-25 column was equilibrated with CO-saturated potassium phosphate buffer (50 mM, pH 7.0), and the rHSA(mutant)-hemeCO solution was passed through the column to remove the dithionite. The eluent was directly connected to an optical quartz cuvette under a 10% CO (in N<sub>2</sub>) atmosphere. The 10% NO (in N<sub>2</sub>) equilibrated buffer was then rapidly injected into the rHSA(mutant)-hemeCO solution, and the time dependence of the decrease in absorption at 418 nm was monitored. The relaxation curves that accompanied the CO dissociation within several minutes were analyzed by fitting to double-exponentials. The CO binding constants [ $K^{\text{CO}} = (P_{1/2}^{\text{CO}})^{-1}$ ] were calculated using  $k_{\text{on}}^{\text{CO}}/k_{\text{off}}^{\text{CO}}$ .

**Magnetic Circular Dichroism (MCD).** The MCD for the 50 mM potassium phosphate-buffered solutions (pH 7.0) of the rHSA(wt)-heme and rHSA(mutant)-heme series (8.0  $\mu\text{M}$ ) under Ar and CO atmospheres were measured using a JASCO J-820 circular dichrometer fitted with a 1.5 T electromagnet at 22 °C. The spectrum was acquired five times to improve signal-to-noise, and each data point was corrected

(14) Collman, J. P.; Brauman, J. I.; Iverson, B. L.; Sessler, J. L.; Moris, R. M.; Gibson, Q. H. *J. Am. Chem. Soc.* **1983**, *105*, 3052–3064.

(15) Traylor, T. G.; Tsuchiya, S.; Campbell, D.; Mitchel, M.; Styne, D.; Koga, N. *J. Am. Chem. Soc.* **1985**, *107*, 604–614.

(16) Rohlfs, R.; Mathews, A. J.; Carver, T. E.; Olson, J. S.; Springer, B. A.; Egeberg, K. D.; Sliger, S. G. *J. Biol. Chem.* **1990**, *265*, 3168–3176.



**Figure 2.** (a) UV-vis absorption and (b) MCD spectral changes of the rHSA(wt)-heme in 50 mM potassium phosphate buffered solution (pH 7.0, 22 °C).

by subtracting the optical rotation observed in the absence of an applied magnetic field.

## Results and Discussion

**Naturally Occurring rHSA(wt)-Hemin.** Our crystal structure analysis revealed that heme is bound within a D-shaped cavity in subdomain IB of rHSA(wt), where the central ferric ion is coordinated by Tyr-161, and the two propionate side chains are coordinated by a triad of basic amino acid residues (Figure 1).<sup>3e</sup> The UV-vis absorption spectrum of the phosphate-buffered solution (50 mM, pH 7.0) of rHSA(wt)-hemin showed a Soret band at 405 nm and the charge-transfer (CT) band of the porphyrin  $\pi\pi^*$  to the  $\text{Fe}^{3+}$   $d\pi$  orbitals at 624 nm (Figure 2a). The spectral pattern and amplitudes were almost constant in the temperature range of 5–40 °C. The dominant feature of the spectrum was quite similar to those of the human or horse heart ferric H93Y recombinant Mb [rMb(H93Y)], in which the proximal histidine (His-93) was replaced with Tyr by site-directed mutagenesis (Table 1).<sup>17,18</sup> Adachi and co-workers showed that the ferric rMb(H93Y) formed a five-coordinate high-spin complex with a single oxygen donor of the proximal

**Table 1.** UV-vis Absorption Spectral Data of the rHSA(wt)-Heme, rHSA(mutant)-Heme and Other Hemoproteins

Hemoproteins	State	$\lambda_{\text{max}}$ (nm)	
		Soret	Visible
rHSA(wt)-Heme <sup>a</sup>	$\text{Fe}^{3+}$	405	501, 534, 624
	$\text{Fe}^{2+}$	419	538, 559(sh), 570
	$\text{Fe}^{2+}\text{CO}$	416	539, 568
HSA-Heme <sup>b</sup>	$\text{Fe}^{3+}$	404	498, 530, 620
	$\text{Fe}^{2+}$	416	534, 570
	$\text{Fe}^{2+}\text{CO}$	418	536, 568
Human rMb(H93Y) <sup>c</sup>	$\text{Fe}^{3+}$	402	480, 520(sh), 598
	$\text{Fe}^{2+}$	427	560
	$\text{Fe}^{2+}\text{CO}$	420	539, 567
Horse Heart rMb(H93Y) <sup>d</sup>	$\text{Fe}^{3+}$	403	487, 524, 599
	$\text{Fe}^{2+}$	429	556
	$\text{Fe}^{2+}\text{CO}$	419	539, 570
FePPIXDME( $\text{CH}_3\text{O}^-$ ) <sup>e</sup>	$\text{Fe}^{3+}$	401	476, 580(sh), 600
FePPIXDME( $p\text{-NO}_2\text{PhO}^-$ ) <sup>f</sup>	$\text{Fe}^{3+}$	402	500, 528, 621
FePPIXDME <sup>g,s</sup>	$\text{Fe}^{3+}$	400	571, 599
	$\text{Fe}^{2+}$	393, 414, 427, 440(sh)	535, 571
rHSA(I142H)-Heme <sup>a</sup>	$\text{Fe}^{2+}\text{CO}$	411	532, 564
	$\text{Fe}^{3+}$	404	501, 533, 619
	$\text{Fe}^{2+}$	424	530, 558
rHSA(I142H/Y161L)-Heme <sup>a</sup>	$\text{Fe}^{2+}\text{CO}$	419	537, 560
	$\text{Fe}^{3+}$	402	533, 620
	$\text{Fe}^{2+}$	426	531(sh), 559
rHSA(I142H/Y161Y)-Heme <sup>a</sup>	$\text{Fe}^{2+}\text{O}_2$	412	537, 573
	$\text{Fe}^{2+}\text{CO}$	419	538, 565
	$\text{Fe}^{3+}$	402	533, 620
rHSA(Y161L/L185H)-Heme <sup>a</sup>	$\text{Fe}^{2+}$	425	532(sh), 559
	$\text{Fe}^{2+}\text{O}_2$	411	538, 576
	$\text{Fe}^{2+}\text{CO}$	419	538, 565
Mb <sup>a,h</sup>	$\text{Fe}^{3+}$	408	528, 620
	$\text{Fe}^{2+}$	422	530, 558
	$\text{Fe}^{2+}\text{O}_2$	412	538, 570
Mb <sup>a,h</sup>	$\text{Fe}^{2+}\text{CO}$	419	537, 560
	$\text{Fe}^{3+}$	409	503, 548(sh), 632
	$\text{Fe}^{2+}$	434	557
	$\text{Fe}^{2+}\text{O}_2$	418	544, 581
	$\text{Fe}^{2+}\text{CO}$	423	541, 579

<sup>a</sup> In 50 mM potassium phosphate buffer (pH 7.0, 22 °C). <sup>b</sup> In 0.1 M phosphate buffer (pH 7.0); ref 22. <sup>c</sup> In 50 mM sodium phosphate buffer (pH 7.0, 20 °C); ref 17. <sup>d</sup> At pH 7–10, 25 °C; ref 18. <sup>e</sup> In  $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH} = 9/1$  (v/v) (25 °C); ref 21. <sup>f</sup> In  $\text{CH}_2\text{Cl}_2$  (25 °C); ref 21. <sup>g</sup> In 0.5%  $\text{Me}_3\text{CeNBr}$ . <sup>h</sup> Horse muscle Mb (Sigma).

Tyr-93 by resonance Raman spectroscopy.<sup>17b</sup> Our absorption spectral data imply that the heme is bound to Tyr-161 of rHSA(wt) and forms a ferric five-coordinate high-spin complex under physiological conditions. Interestingly, the CT absorptions of the rHSA(wt)-hemin appeared at a higher wavelength ( $\lambda_{\text{max}} = 624$  nm) compared to rMb(H93Y) ( $\lambda_{\text{max}} = 598$ –599 nm). Dawson and co-workers classified the CT bands of the oxygen-ligated hemins into two groups: the first at around 600 nm for rMb(H93Y) and the methoxide ( $\text{CH}_3\text{O}^-$ ) complex of  $\text{Fe}^{3+}$  protoporphyrin IX dimethyl ester ( $\text{Fe}^{3+}\text{PPIXDME}$ ), and the second at around 620 nm for  $p$ -nitrophenolate ( $p\text{-NO}_2\text{PhO}^-$ ) or the acetate complex of  $\text{Fe}^{3+}\text{PPIXDME}$ , in which the nonoccupied  $\pi^*$  orbitals of the fifth ligand interacts with the  $\text{Fe}^{3+}$   $d\pi$  orbitals and, in turn, lowered the energy level of the CT transition (Table 1).<sup>19</sup> The rHSA(wt)-hemin definitely belongs to the latter group, which suggests that the axial coordination

- (17) (a) Adachi, S.; Nagano, S.; Watanabe, Y.; Ishimori, K.; Morishima, I. *Biochim. Biophys. Res. Commun.* **1991**, *180*, 138–144. (b) Adachi, S.; Nagano, S.; Ishimori, K.; Watanabe, Y.; Morishima, I.; Egawa, T.; Kitagawa, T.; Makino, R. *Biochemistry* **1993**, *32*, 241–252.  
 (18) Hildebrand, D. P.; Burk, D. L.; Maurus, R.; Ferrer, J. C.; Brayer G. D.; Mauk, A. G. *Biochemistry* **1995**, *34*, 1997–2005.  
 (19) Pond, A. E.; Roach, M. P.; Sono, M.; Rux, A. H.; Franzen, S.; Hu, R.; Thomas, M. R.; Wilks, A.; Dou, Y.; Ikeda-Saito, M.; Ortiz de Montellano, P. R.; Woodruff, W. H.; Boxer, S. G.; Dawson, J. H. *Biochemistry* **1999**, *38*, 7601–7608.

of Tyr-161 to the hemin is weaker than that of rMb(H93Y) and Fe<sup>3+</sup>PPIXDME(CH<sub>3</sub>O<sup>-</sup>). This is consistent with the observation that the Fe<sup>3+</sup>-O(phenolate) distance in the crystal structure of the rHSA(wt)-hemin (2.78 Å) is greater than that for rMb(H93Y) (1.91 Å).<sup>3e</sup>

We then employed MCD spectroscopy to elucidate the axial coordination environment of the rHSA(wt)-hemin. MCD is a powerful probe of the oxidation state, spin state, and the nature of the axial ligand in heme system and has frequently been used as a method of comparison between synthetic iron porphyrins of known axial ligation and newly discovered hemoproteins of unknown ligation.<sup>20</sup> The ferric rHSA(wt)-hemin showed a characteristic MCD pattern with two distinct troughs in the visible region (550, 642 nm) (Figure 2b), which was more similar to that of the five-coordinate Fe<sup>3+</sup>PPIXDME (*p*-NO<sub>2</sub>-PhO<sup>-</sup>) than to that of the Fe<sup>3+</sup>PPIXDME(CH<sub>3</sub>O<sup>-</sup>).<sup>19,21</sup> The MCD of the rHSA(wt)-hemin therefore also supports the formation of a five-coordinate high-spin hemin complex with weak axial ligation by Tyr-161.

**Reduced Ferrous rHSA(wt)-Heme.** Reduction of the ferric rHSA(wt)-hemin by the addition of sodium dithionite under an Ar atmosphere gave a ferrous heme complex with a broad Soret band at 419 nm ( $\Delta\lambda_{1/2} = 61$  nm) and two definite Q-bands at 538 and 570 nm (Figure 2a). This is in significant contrast to human ferrous rMb(H93Y) in a five-coordinate high-spin complex, which exhibits a similar spectrum to deoxy Mb with a sharp Soret band and single Q-band absorption around 560 nm (Table 1).<sup>17,18</sup> The shoulder at 559 nm in the spectrum of the rHSA(wt)-heme is probably due to a ferrous five-coordinate complex, but this clearly coexists with another species. One possible candidate is a six-coordinate low-spin complex. Casella and co-workers proposed that the reduced HSA-heme contains a six-coordinate heme.<sup>22</sup> Nevertheless, the MCD spectrum of the ferrous rHSA(wt)-heme (Figure 2b) was quite different from the well-known shape of the six-coordinate low-spin heme derivatives, such as cytochrome *b*<sub>5</sub> and bisimidazole-ligated Fe<sup>2+</sup>PPIXDME, which show a sharp and intense Faraday A term corresponding to the  $\alpha$  band.<sup>20c</sup>

Another possibility is a four-coordinate intermediate spin state ( $S = 1$ ) not found in natural Mb. Phosphate-buffered solutions (pH 7.0) of 0.5% (w/v) *N*-cetyltrimethylammonium bromide (CetMe<sub>3</sub>NBr) micelles containing dissolved Fe<sup>2+</sup>PPIXDME showed a multiple broad Soret band ( $\Delta\lambda_{1/2} = 73$  nm) and well-defined  $\beta$  and  $\alpha$  bands (535 and 571 nm) (Table 1, see Figure S1a), a spectral pattern consistent with a four-coordinate Fe<sup>2+</sup>-mesoporphyrin IX dimethyl ester in the CetMe<sub>3</sub>NBr suspension.<sup>23</sup> This observation suggests that the strong  $\beta$  and  $\alpha$  bands (538, 570 nm) in the UV-vis absorption spectrum of the rHSA(wt)-heme complex also derived from a ferrous four-coordinate complex. The micellar solution of Fe<sup>2+</sup>PPIXDME showed

complicated MCD bands in the Soret region and two positive peaks (522, 562 nm) and one trough (579 nm) in the visible region (see Figure S1b). The typical MCD of five-coordinate deoxy Mb is shown in Figure 4b (vide infra). Comparison of these data with the MCD spectral pattern of ferrous rHSA(wt)-heme suggests that the latter involves both important features of four- and five-coordinate heme complexes (Figure 2b). Therefore, we conclude that the reduced ferrous rHSA(wt)-heme is in an unusual mixture of a five-coordinate high-spin complex ( $S = 5/2$ ) with Tyr-161 and a four-coordinate intermediate spin state ( $S = 1$ ) under an Ar atmosphere. The estimated ratio of the five- and four-coordinate complexes is approximately 1/1.

Upon the addition of O<sub>2</sub> gas to this solution, the central ferrous ion was rapidly autoxidized even at low temperature ( $\sim 0$  °C), and the UV-vis absorption spectrum returned to the initial ferric complex. On the other hand, a carbonyl complex was formed at room temperature and exhibited a very similar absorption ( $\lambda_{\max} = 416, 539, 568$  nm) to human and horse rMb(H93Y)CO (Figure 2a, Table 1).<sup>17,18</sup> The MCD spectrum of the rHSA(wt)-hemeCO showed simple Faraday A terms associated with the porphyrin  $\pi-\pi^*$  transitions, which are typical of a low-spin carbonyl heme (Figure 2b).<sup>20</sup> The rHSA(wt)-hemeCO could be a diamagnetic low-spin complex with a phenolate ligand (Tyr-161) similar to what was found for rMb(H93Y).

In our blood stream, the most avid carrier of hemin is the specific heme-binding protein, hemopexin.<sup>24,25</sup> The binding constant of hemopexin for hemin is 10<sup>4</sup>-fold higher than HSA. However, due to the extremely low abundance of hemopexin in plasma (<17  $\mu$ M), HSA acts as a significant depot of hemin in the circulation. The hemin binding to these proteins not only conserves the porphyrin iron and channels it to the specific catabolism site but it also prevents its toxic effects, such as the catalysis of hydroxyl radical production. Furthermore, HSA-hemin exhibits little peroxidase or catalase activities.<sup>22</sup> The weak axial coordination of phenolate to HSA-bound hemin may therefore have evolved for (1) easy release and transfer to hemopexin in the blood stream, and (2) maintenance of the antioxidative homeostasis in the extracellular fluids of our body.


**Genetic Engineered rHSA(mutant) Complexed with Hemin.** The detailed architecture of the heme-binding site in HSA revealed by our crystallographic studies allows us to design mutagenesis experiments to construct a tailor-made heme pocket for stable O<sub>2</sub> binding. Tyr-161 was the first candidate considered for site-directed mutagenesis to introduce a proximal histidine; however, the Y161H mutation was not done because our simulations indicated that the distance from N<sub>ε</sub>(H161) to Fe-(heme) would be too great (4.0 Å). Instead, modeling experiments suggested that the favorable positions for the axial imidazole insertion would be Ile-142 and Leu-185 (Figure 1). The N<sub>ε</sub>(histidine)-Fe distances were estimated to be 2.31 Å for H142 and 2.69 Å for H185 (compared to 2.18 Å for Mb). We therefore designed and produced a single mutant I142H and three double mutants I142H/Y161L, I142H/Y161F, and Y161L/L185H (see Experimental Section).

The UV-vis absorption and MCD spectra of the rHSA(I142H/Y161L)-hemin and rHSA(I142H/Y161F)-hemin are

- (20) (a) Collman, J. P.; Basolo, F.; Bunnenberg, E.; Collins, T. J.; Dawson, J. H.; Ellis, P. E., Jr.; Marrocco, M. L.; Moscovitz, A.; Sessler, J. L.; Szymanski, T. *J. Am. Chem. Soc.* **1981**, *103*, 5636–5648. (b) Cheek, J.; Dawson, J. H. *Magnetic Circular Dichroism Spectroscopy of Heme Proteins and Model Systems*. In *The Porphyrin Handbook*; Kadish, K. M., Smith, K. M., Guillard, R., Eds.; Academic Press: San Diego, 2000; Vol. 7, pp 339–369. (c) Svasits, E. W.; Dawson, J. H. *Inorg. Chim. Acta.* **1986**, *123*, 83–86.
- (21) Nozawa, T.; Okubo, S.; Hatano, M. *J. Inorg. Biochem.* **1980**, *12*, 253–267.
- (22) Monzani, E.; Bonafè, B.; Fallarini, A.; Redaelli, C.; Casella, L.; Minchiotti, L.; Galliano, M. *Biochim. Biophys. Acta* **2001**, *1547*, 302–312.
- (23) Geibel, J.; Cannon, J.; Campbell, D.; Traylor, T. G. *J. Am. Chem. Soc.* **1978**, *100*, 3575–3585.

(24) Tolosano, E.; Altruda, F. *DNA Cell Biol.* **2002**, *21*, 297–306.

(25) Paoli, M.; Anderson, B. F.; Baker, H. M.; Morgan, W. T.; Smith, A.; Baker, E. N. *Nat. Struct. Biol.* **1999**, *6*, 926–931.




**Figure 3.** UV-vis absorption spectral changes of the (a) rHSA(I142H/Y161L)-heme and (b) rHSA(I142H/Y161F)-heme in 50 mM potassium phosphate buffered solution (pH 7.0, 8 °C).

essentially the same in their general features (Figure 3 and Figure S2). The strong absorption band due to the porphyrin-to-metal CT was weakened because of the Y161L and Y161F mutations (Figure 3). Both MCD spectra showed similar S-shaped patterns in the Soret band region, which resembled that of ferric Mb (see Figure S2).<sup>26</sup> It is known that two water molecules are located in the heme pocket of ferric Mb.<sup>27</sup> One water axially coordinates to the sixth position of the central ferric ion of the heme to produce the aquo complex, and the other one is at the rear of the pocket, hydrogen bonded to the first water. A great number of MCD studies on synthetic iron porphyrins and hemoproteins have demonstrated that the spectral shape in the Soret region can be used as a qualitative marker of the spin state and axial coordination environment.<sup>20</sup> Vickery and co-workers found that (i) the Soret MCD intensity of the ferric Mb with different anions at the six-coordinate position was correlated with the amount of low-spin component formed,

(26) Vickery, L.; Nozawa, T.; Sauer, K. *J. Am. Chem. Soc.* **1976**, *98*, 343–350.

(27) Springer, B. A.; Sligar, S. G.; Olson, J. S.; Phillips, G. N., Jr. *Chem. Rev.* **1994**, *94*, 699–714.



**Figure 4.** MCD spectral changes of the (a) rHSA(I142H/Y161L)-heme and (b) native Mb in 50 mM potassium phosphate buffered solution (pH 7.0, 22 °C).<sup>30</sup>

and (ii) the shape of the band is sensitive to the nature of the sixth ligand.<sup>26</sup> Our MCD results suggest that both the rHSA(I142H/Y161L)-hemin and rHSA(I142H/Y161F)-hemin are in predominantly ferric high-spin complexes having a water molecule as the sixth ligand.

**O<sub>2</sub> and CO Binding to Ferrous rHSA(mutant)-Heme.** The rHSA(mutant)-hemin was easily reduced to the ferrous complex by adding a small molar excess of aqueous sodium dithionite under an Ar atmosphere. A single broad absorption band ( $\lambda_{\text{max}} = 559$  nm) in the visible region of the rHSA(I142H/Y161L)-heme and rHSA(I142H/Y161F)-heme was similar to that observed for deoxy Mb<sup>28</sup> or the chelated heme in DMF,<sup>29</sup> indicating the formation of a five-*N*-coordinate high-spin complex (Figure 3, Table 1). The spectral features and amplitude were unaltered in the temperature range of 0–25 °C. The heme therefore appears to be accommodated in the mutated heme pocket with an axial coordination involving His-142. Upon exposure of the rHSA(I142H/Y161L)-heme and rHSA(I142H/

(28) Antonini, E.; Brunori, M. *Hemoglobin and Myoglobin in Their Reactions with Ligands*; North-Holland Pub.: Amsterdam, 1971; p 18.

(29) Traylor, T. G.; Chang, C. K.; Geibel, J.; Berzins, A.; Mincey, T.; Cannon, J. *J. Am. Chem. Soc.* **1979**, *101*, 6716–6731.


Y161F)-heme solutions to O<sub>2</sub>, the UV-vis absorptions immediately changed to that of the O<sub>2</sub> adduct complex at 0–25 °C (Figure 3).<sup>28,29</sup> After flowing CO gas, these hemoproteins produced stable carbonyl complexes.

The MCD spectra of the deoxy and carbonyl rHSA(I142H/Y161L)-heme are shown in Figure 4a. The Soret MCD of the deoxy state under anaerobic conditions is dominated by an intense positive peak at 435 nm, as would be expected for the Faraday *C* terms anticipated for the high-spin Fe<sup>2+</sup> porphyrin.<sup>20a,26</sup> On the other hand, the rHSA(I142H/Y161L)CO exhibited S-shaped MCDs which correspond to the *A* term bands for the diamagnetic Fe<sup>2+</sup> porphyrin.<sup>20a,26</sup> These spectra are very similar to those of the high-spin deoxy Mb and low-spin MbCO measured in identical conditions (Figure 4b). Our MCD results clearly show that the central ferrous ion of the heme is coordinated by His-142 in the heme pocket and forms a five-*N*-coordinate high-spin complex under an Ar atmosphere, which converts to the low-spin diamagnetic form by the binding of CO. The rHSA(I142H/Y161F)-heme complex had the same MCD spectral features as rHSA(I142H/Y161L)-heme (data not shown).


The single mutant rHSA(I142H)-heme complex, which retains Y161, could not bind O<sub>2</sub>. The polar phenolate residue at the top of the porphyrin plane is likely to accelerate the proton-driven oxidation of the Fe<sup>2+</sup> center. This rapid autoxidation is also observed in the rMb(H64Y) mutants, in which the distal histidine (His-64) was substituted with Tyr, thus introducing a potentially anionic nucleophile near to the O<sub>2</sub> coordination site.<sup>31</sup> In contrast, replacement of Tyr-161 in rHSA(I142H)-heme by Leu or Phe enhanced the stabilization of the O<sub>2</sub> adduct complex. In the rHSA(Y161L/L185H)-heme, the proximal histidine coordinated to the central ferrous ion from the opposite side of the porphyrin platform also allows O<sub>2</sub> binding to the heme. The lifetimes for the decays of the dioxygenated rHSA(I142H/Y161L)-heme, rHSA(I142H/Y161F)-heme, and rHSA(Y161L/L185H)-heme are all 3–5 min at 20 °C.

To evaluate the kinetics of the O<sub>2</sub> and CO bindings to the rHSA(mutant)-heme, laser flash photolysis experiments were carried out.<sup>14,15</sup> The transient absorption spectra of the photodissociated product of the rHSA(I142H/Y161L)-hemeCO displayed a negative absorbance at 417 nm, due to the disappearance of the carbonyl complex, and a positive absorbance at 435 nm, which is attributed to the deoxy form (Figure 5). The transient absorption spectra in the time range from 0.1 μs to 8.0 ms with an isosbestic point at 401, 426, and 458 nm were superimposed on the static difference spectrum of the deoxy minus carbonyl compound (Figure 5, red line). They illustrate the process of reassociation of CO and are consistent with the formation of the ferrous five-*N*-coordinate high-spin complex after the laser pulse irradiation.

It is noteworthy that the absorbance decays accompanying the CO recombinations to these rHSA(mutant)-heme were composed of double-exponential profiles, which are normally not observed in Mb (Figure 6a). The ratio of the amplitude of the fast and slow phases was approximately 3:2 for the rHSA(I142H/Y161L)-heme, 5:1 for the rHSA(I142H/Y161F)-heme and 3:1 for the rHSA(Y161L/L185H)-heme. On the other hand,



**Figure 5.** Transient absorption spectra of the photodissociated product of the rHSA(I142H/Y161L)-hemeCO after the laser flash photolysis at 22 °C. The red-line represents the static spectrum of deoxy minus carbonyl compound in Figure 3a.



**Figure 6.** Absorption decay of CO rebinding to the rHSA(I142H/Y161F)-heme after the laser flash photolysis at 22 °C; the kinetics was composed of two phases and relaxation curve was fitted by double-exponentials. (b) Absorption decay of O<sub>2</sub> rebinding to the rHSA(I142H/Y161F)-heme after the laser flash photolysis at 22 °C; the kinetics was fitted by single-exponential relaxation curve.

the rebinding of O<sub>2</sub> to the rHSA(mutant)-heme followed a simple monophasic decay (Figure 6b). From numerous investigations on synthetic model hemes, it has been shown that a bending

(30) The spectra of Mb are consistent with other results reported elsewhere; refs 20, 26.

(31) Springer, B. A.; Egeberg, K. D.; Slinger, S. G.; Rohlf, R. J.; Mathews, A. J.; Olson, J. S. *J. Biol. Chem.* **1989**, *264*, 3057–3060.




Figure 7. Structural models of the hemeO<sub>2</sub> sites of rHSA(I142H/Y161F)-heme and rHSA(I142L/Y161L)-heme, and comparison to Mb.<sup>12,32</sup>

strain in the proximal base coordination to the central Fe<sup>2+</sup> atom, the “proximal-side steric effect”, can both increase the dissociation rate and decrease the association rate for CO, whereas it increases the O<sub>2</sub> dissociation rate without greatly altering the kinetics of O<sub>2</sub> association.<sup>14,15</sup> One possible explanation is that there may be two different geometries of the axial histidine (His-142 or His-185) coordination to the central ferrous ion of the heme, each one accounting for a component of the biphasic kinetics of CO rebinding. Marden and co-workers also reported a similar two-phase kinetics in CO association with HSA-heme and interpreted it as indicating that there are two different orientations of the porphyrin ring in a single site on HSA.<sup>10</sup> In our case, the alternative geometries may arise because crystallographic analysis suggests that the heme molecule appears able to bind into the narrow cavity of subdomain IB in two orientation that are related by a 2-fold rotation about the 5,15-*meso* axis of the heme (180° rotational isomers). It appears that the asymmetric hydrophobic 3,8-divinyl groups at the porphyrin periphery may occupy different positions that result in a shift of the Fe<sup>2+</sup> center, forming the two different geometries of the axial imidazole coordination of histidine (Figure 7).

In general, the crystal structures of natural hemoproteins have shown that the prosthetic heme group is bound in a single orientation. On the other hand, in solution, <sup>1</sup>H NMR spectra frequently exhibit two sets of heme (or hemin) resonances, which arise from alternative orientations of the porphyrin plane.<sup>33</sup> This orientational disorder is most readily detected in the ferric low-spin state, which shows extraordinary porphyrin

2,7,12,18-CH<sub>3</sub> contact shifts.<sup>34</sup> The amount of the minor species ranges from a few percent in Mb to 40% in insect Hb (*CTT* HbIII).<sup>35</sup> Reconstitution techniques have made significant contributions to clarify this molecular equilibrium; the heme in Hb and Mb can be easily removed under acidic conditions and the resulting apoprotein may be reconstituted by adding back the heme to produce the holoprotein.<sup>36</sup> The incorporation of hemin into apoMb is complete within 1 ms, but the initial complex does not distinguish the two possible orientations of the porphyrin ring.<sup>34</sup> As a result, freshly reconstituted Mb contains an equimolar 1/1 mixture of the two conformers; subsequent heme rearrangement is extremely slow (≈13 h). The influence of the heme orientation on the functional properties appears to be very dependent on the particular protein. In *CTT* HbIII, the O<sub>2</sub> binding affinity depends on the heme orientation.<sup>37</sup> On the other hand, the equilibrium and kinetic parameters for O<sub>2</sub> and CO binding to the reconstituted human Mb are unaffected by the slow heme rearrangement.<sup>38,39</sup>

Our attempts to determine the ratio of the two hemin orientations of the rHSA(I142H/Y161L)-hemin by <sup>1</sup>H NMR spectroscopy unfortunately failed. The downfield spectra of the

(32) The model of Mb was prepared on the basis of crystal structure coordinate of MbO<sub>2</sub> (code: 1MBO, Phillips, S. E. *J. Mol. Biol.* **1980**, *142*, 531–554.). The coordinated O<sub>2</sub> shows a hydrogen bond with N<sub>ε</sub>(His-64) and hydrogen bond network through H<sub>2</sub>O (light-blue circle) within the distal pocket.

- (33) La Mar, G. N.; Satterlee, J. D.; de Ropp, J. S. Nuclear Magnetic Resonance of Hemoprotein. In *The Porphyrin Handbook*; Kadish, K. M., Smith, K. M., Guillard, R., Eds.; Academic Press: San Diego, 2000; Vol. 5, pp 185–298.
- (34) (a) Jue, T.; Krishnamoorthi, R.; La Mar, G. N. *J. Am. Chem. Soc.* **1983**, *105*, 5701–5703. (b) La Mar, G. N.; Toi, H.; Krishnamoorthi, R. *J. Am. Chem. Soc.* **1984**, *106*, 6395–6401.
- (35) (a) La Mar, G. N.; Davis, N. L.; Parish, D. W.; Smith, K. M. *J. Mol. Biol.* **1983**, *168*, 887–896. (b) La Mar, G. N.; Smith, K. M.; Gersonde, K.; Sick, H.; Overcamp, M. *J. Biol. Chem.* **1980**, *255*, 66–70.
- (36) Hayashi, T.; Hisaeda, Y. *Acc. Chem. Res.* **2002**, *35*, 35–43.
- (37) Gersonde, K.; Sick, H.; Overcamp, M.; Smith, K. M.; Parish, D. W. *Eur. J. Biochem.* **1986**, *157*, 393–404.
- (38) Light, W. R.; Rohlfis, R. J.; Palmer, G.; Olson, J. S. *J. Biol. Chem.* **1987**, *262*, 46–52.
- (39) Aojula, H. S.; Wilson, M. T.; Morrison, I. G. *Biochem. J.* **1987**, *243*, 205–210.

**Table 2.** O<sub>2</sub> Binding Parameters of the rHSA(mutant)-Heme in 50 mM Potassium Phosphate Buffer Solution (pH 7.0) at 22 °C<sup>a</sup>

Hemoproteins	$k_{on}^{O_2}$ ( $\mu\text{M}^{-1}\text{s}^{-1}$ )	$k_{off}^{O_2}$ ( $\text{s}^{-1}$ )		$P_{1/2}^{O_2}$ (Torr)	
		I	II	I	II
rHSA(I142H/Y161L)-Heme	7.5	0.22	1.7	18	134
rHSA(I142H/Y161F)-Heme	20	0.10	0.99	3	31
rHSA(Y161L/L185H)-Heme	31	0.20	2.1	4	41
Hb $\alpha$ (R-state) <sup>b</sup>	33 <sup>c</sup>	0.013 <sup>d</sup>		0.24	
Mb <sup>e,f</sup>	14	0.012		0.51	
rMb(H64L) <sup>f</sup>	98	4.1		26	
rMb(H64F) <sup>f</sup>	75	10		82	
RBC <sup>g</sup>				8	

<sup>a</sup> Number I or II indicates species I or II. <sup>b</sup> Human Hb  $\alpha$ -subunit. <sup>c</sup> In 0.1 M phosphate buffer (pH 7.0, 21.5 °C); ref 40. <sup>d</sup> In 50 mM phosphate buffer (pH 7.0, 20 °C); ref 41. <sup>e</sup> Sperm whale Mb. <sup>f</sup> In 0.1 M potassium phosphate buffer (pH 7.0, 20 °C); ref 16. <sup>g</sup> Human red cell suspension. In isotonic buffer (pH 7.4, 20 °C); ref 42.

**Table 3.** CO Binding Parameters of the rHSA(mutant)-Heme in 50 mM Potassium Phosphate Buffer Solution (pH 7.0) at 22 °C<sup>a</sup>

Hemoproteins	$k_{on}^{CO}$ ( $\mu\text{M}^{-1}\text{s}^{-1}$ )		$k_{off}^{CO}$ ( $\text{s}^{-1}$ )		$P_{1/2}^{CO}$ (Torr)	
	I	II	I	II	I	II
rHSA(I142H/Y161L)-Heme	2.0	0.27	0.013	0.079	0.0053	0.24
rHSA(I142H/Y161F)-Heme	6.8	0.72	0.009	0.061	0.0011	0.068
rHSA(Y161L/L185H)-Heme	3.7	0.35	0.012	0.077	0.0026	0.18
Hb $\alpha$ (R-state) <sup>b</sup>	4.6 <sup>c</sup>		0.009 <sup>d</sup>		0.0016 <sup>e</sup>	
Mb <sup>f,g</sup>	0.51		0.019		0.030	
rMb(H64F) <sup>g</sup>	4.5		0.054		0.0097	

<sup>a</sup> Number I or II indicates species I or II. <sup>b</sup> Human Hb  $\alpha$ -subunit. <sup>c</sup> In 50 mM potassium phosphate buffer (pH 7.0, 20 °C); ref 45. <sup>d</sup> In 0.1 M phosphate buffer (pH 7.0, 20 °C); ref 44. <sup>e</sup> Calculated from  $k_{on}^{CO}/k_{off}^{CO}$ . <sup>f</sup> Sperm whale Mb. <sup>g</sup> In 0.1 M potassium phosphate buffer (pH 7.0, 20 °C); refs 16, 48.

rHSA(I142H/Y161L)-hemin did not show sharp resonances of the four porphyrin CH<sub>3</sub> groups. Other trials to convert the rHSA-(I142H/Y161L)-hemin in the low-spin azide adduct complex,<sup>33</sup> which is much better suited for the <sup>1</sup>H NMR investigation, also failed even with the addition of a large excess of ligand. In any case, the amplitude ratio of the two phases observed for the CO association to rHSA(mutant)-heme was always the same, independent of time after preparation.

**O<sub>2</sub> and CO Binding Parameters.** By analyzing the CO/O<sub>2</sub> competitive binding following laser flash photolysis,<sup>14,15</sup> we obtained the association rate constants for O<sub>2</sub> ( $k_{on}^{O_2}$ ) and the O<sub>2</sub> binding affinities [ $P_{1/2}^{O_2} = (K^{O_2})^{-1}$ ] for the rHSA(I142H/Y161L)-heme, rHSA(I142H/Y161F)-heme and rHSA(Y161L/L185H)-heme (Table 2). From eq 6, variation in  $k_{on}^{CO}$  arising from the two geometries of the His coordination (the faster phase is defined as species I and the slower phase is defined as species II) yielded two different O<sub>2</sub> binding affinities. In species I, the proximal His may coordinate to the central ferrous ion without strain, whereas in species II, the ligation may involve some distortion, resulting in weaker O<sub>2</sub> binding (Figure 7). The absorbance decay accompanying the CO dissociation from the rHSA(mutant)-hemeCO by the replacement with NO also showed double-exponential profiles, giving two values of  $k_{off}^{CO}$  (Table 3). The proximal-side steric effect generally increases the dissociation rate for CO,<sup>14,15</sup> a result that is quite consistent with our interpretation that there are two orientation isomers of the heme (the larger component of  $k_{off}^{CO}$  originating from species II).

The  $P_{1/2}^{O_2}$  values of the rHSA(mutant)-heme were determined to be 3–18 and 31–134 Torr for species I and II, respectively. Thus even the O<sub>2</sub> binding affinities of species I were 6–75-

fold lower than those of native Hb $\alpha$  (R-state) and Mb.<sup>16,40–42</sup> Kinetically, these low affinities for O<sub>2</sub> were due to an 8–18-fold increase in the O<sub>2</sub> dissociation rate constants. Neutron diffraction studies of MbO<sub>2</sub> revealed that there is a direct hydrogen bond between the distal His-64 and the coordinated O<sub>2</sub> (Figure 7).<sup>43</sup> The high-resolution X-ray crystallographic structure of Hb $\alpha$ O<sub>2</sub> also suggested a similar interaction in the heme pocket.<sup>44</sup> In both hemoproteins, the distal His stabilizes the bound O<sub>2</sub> by about  $-1.4$  kcal mol<sup>-1</sup> due to the hydrogen bonding. On the basis of the mutagenesis studies on sperm whale rMb, Rohlfis and co-workers demonstrated that the replacement of His-64 with apolar amino acid residues (Leu or Phe) results in loss of the hydrogen bonding, and markedly increased the O<sub>2</sub> dissociation rates (342–833-fold higher than Mb).<sup>16</sup> In the rHSA(mutant)-heme, the dioxxygenated heme is buried in the core of the hydrophobic cavity without any counterpart for the hydrogen bond; thus the even small  $k_{off}^{O_2}$  values for species I are greater than those of Hb $\alpha$  and Mb. In species II, the proximal-side steric effect could further increase the dissociation rates and cause a large decline in the O<sub>2</sub> binding affinity. In contrast, the binding parameters of CO to the rHSA(mutant)-heme (species I) exhibited similar values of Hb $\alpha$  ( $\leq 3$ -fold),<sup>45,46</sup> because the coordinated CO in Hb $\alpha$  does not form a hydrogen bond with the distal His-64.<sup>47</sup>

Comparison of the O<sub>2</sub> binding parameters for rHSA(I142H/Y161L)-heme and rHSA(I142H/Y161F)-heme shows that the presence of a Phe rather than Leu at position 161 results in 6-fold and 4-fold increases in the O<sub>2</sub> binding affinity for species I and II, respectively. This is mainly due to an increase in the O<sub>2</sub> association rate constant (Table 2). The same trend was observed for CO binding (3-fold increase in  $k_{on}^{CO}$ ) (Table 3). The substitution of Leu-161 (102 Å<sup>3</sup>) by Phe-161 (137 Å<sup>3</sup>)<sup>49</sup> replaces an isopropyl group with a rigid benzyl group within the heme pocket. In I142H/Y161L, the small side-chain of Leu-161 may allow free rotation of the side-chain of neighboring Leu-185, thereby reducing the volume on the distal-side of the porphyrin plane (Figure 7). Actually, modeling and experimental studies suggest that His-185 in Y161L/L185H can coordinate to the central ferrous ion of the heme. On the other hand, the bulkier aromatic side-chain of Phe-161 may prevent rotation of the isopropyl group of Leu-185 and thereby provide greater room of the distal pocket; this might allow easier access to the heme Fe atom and account for the increased association rates for O<sub>2</sub> and CO.

## Conclusion

HSA exploits weak axial coordination by Tyr-161 to bind hemin into the heme pocket. Reduction of the central ferric ion partly disrupts the Fe–O(phenolate) bond and produces unusual

- (40) Gibson, Q. H. *J. Biol. Chem.* **1970**, *245*, 3285–3288.  
 (41) Olson, J. S.; Andersen, M. E.; Gibson, Q. H. *J. Biol. Chem.* **1971**, *246*, 5919–5923.  
 (42) Imai, K.; Morimoto, H.; Kotani, M.; Watari, H.; Hirata, W.; Kuroda, M. *Biochim. Biophys. Acta* **1970**, *200*, 189–197.  
 (43) Phillips, S. E. V.; Schoenborn, B. P. *Nature* **1981**, *292*, 81–82.  
 (44) Shaanan, B. *J. Mol. Biol.* **1983**, *171*, 31–59.  
 (45) Steinmeier, R. C.; Parkhurst, L. J. *Biochemistry* **1975**, *14*, 1564–1571.  
 (46) Sharma, V. S.; Schmidt, M. R.; Ranney, H. M. *J. Biol. Chem.* **1976**, *251*, 4267–4272.  
 (47) Hanson, J. C.; Schoenborn, B. P. *J. Mol. Biol.* **1981**, *153*, 117–146.  
 (48) rMb(H64L) exhibited an abnormally large CO binding affinity and  $k_{on}^{CO}$  compared to those of other mutants; ref 16.  
 (49) Creighton, T. E. *Proteins: Structures and Molecular Properties*; W. H. Freeman and Co.: New York, 1983; p 242.

ferrous four-coordinate intermediate-spin state hemoprotein. We have engineered mutant rHSA-heme complexes which can bind O<sub>2</sub> reversibly with an affinity that is only 1 order of magnitude lower than the affinity of O<sub>2</sub> for Hb $\alpha$  (R-state) and Mb. The principal modifications to the heme pocket that are required to confer reversible O<sub>2</sub> binding are (1) replacement of Tyr-161, the endogenous anionic nucleophile, by hydrophobic amino acid (Leu or Phe), and (2) introduction of His as a proximal base at position Ile-142 or Leu-185 (either side of the porphyrin ring plane). The transport of O<sub>2</sub> by the rHSA-heme could be of tremendous clinical importance not only as a red cell substitute but also as an O<sub>2</sub>-providing therapeutic reagent. Although a number of Hb-based O<sub>2</sub> carriers have already been developed, the administration of these materials often elicits an acute increase in blood pressure by vasoconstriction.<sup>50–52</sup> This side-effect is caused by the rapid capture of the endothelial-derived relaxing factor, namely NO, by Hb that has leaked through the vascular endothelium. In contrast, our rHSA(mutant)-heme would not induce such hypertension, because the albumin carrier has low permeability through the muscle capillary pore.<sup>53</sup>

- (50) Tsuchida, E. Perspectives of Blood Substitutes. In *Blood Substitutes: Present and Future Perspectives*; Tsuchida, E., Ed.; Elsevier Science: Lausanne, 1998; pp 1–14.
- (51) Winslow, R. M. *Annu. Rev. Med.* **1999**, *50*, 337–353.
- (52) Squires, J. E. *Science* **2002**, *295*, 1002–1005.
- (53) Tsuchida, E.; Komatsu, T.; Matsukawa, Y.; Nakagawa, A.; Sakai, H.; Kobayashi, K.; Suematsu, M. *J. Biomed. Mater. Res.* **2003**, *64A*, 257–261.

Our results on several mutants have also shown that modification of the distal-side of the heme pocket has a measurable effect on O<sub>2</sub> binding affinity (compare Leu-161 and Phe-161). To develop this promising O<sub>2</sub> carrier as a blood substitute, further work using a combined mutagenic and synthetic approach is required; (1) additional mutations, e.g. an introduction of a distal base which in Mb and Hb $\alpha$  forms a hydrogen bond with the coordinated O<sub>2</sub>, may help to stabilize the O<sub>2</sub> adduct complex, and (2) small modifications to the heme structure designed to adjust its position within the pocket interior but without straining the proximal His coordination, may improve and modulate the O<sub>2</sub> binding ability. To aid these modifications, crystal structural analysis of rHSA(mutant)-heme complexes is now underway.

**Acknowledgment.** This work was supported by a Grant-in-Aid for Scientific Research (No. 16350093) from JSPS, a Grant-in-Aid for Exploratory Research (No. 16655049) from MEXT Japan, Health Science Research Grants (Regulatory Science) from MHLW Japan, and Wellcome Trust (UK). The work at Imperial College London was partially carried out as the Japan-UK Research Cooperative Program (Joint Project) of JSPS.

**Supporting Information Available:** UV–vis absorption and MCD spectra of FePPIXDME, MCD spectra of the ferric rHSA-(mutant)-hemin and aquo-metMb. This material is available free of charge via the Internet at <http://pubs.acs.org>.

JA054819U



## Albumin Clusters: Structurally Defined Protein Tetramer and Oxygen Carrier Including Thirty-Two Iron(II) Porphyrins

Teruyuki Komatsu,\* Yukiko Oguro, Akito Nakagawa, and Eishun Tsuchida\*

Advanced Research Institute for Science and Engineering, Waseda University, 3-4-1 Okubo, Shinjuku-ku, Tokyo 169-8555, Japan

Received June 30, 2005; Revised Manuscript Received August 10, 2005

Recombinant human serum albumin (rHSA) clusters have been synthesized and physicochemically characterized. Cross-linking between the Lys groups of the core albumin and a unique Cys-34 of the shell albumins with an *N*-succinimidyl-6-[3'-(2-pyridyldithio)propionamido]hexanoate produced the structurally defined rHSA trimer and tetramer. MALDI-TOF-MS showed a single peak with the triple and quadruple masses of rHSA. Their molar ellipticities and the isoelectric points ( $pI = 4.8$ ) are all identical to those of the monomer, suggesting that the essential structures of the albumin units were intact. TEM observations demonstrated a uniform morphology of the rHSA tetramer with a diameter of 20–30 nm. The circulation half-life ( $\tau_{1/2}$ ) of the  $^{125}\text{I}$ -labeled rHSA tetramer in rat (5.5 h) was significantly longer than that of the monomer (2.3 h) due to the low ratio of the distribution phase ( $\alpha$ -phase). A total of 24 and 32 molecules of the synthetic iron(II) porphyrins (FePs) are incorporated into the hydrophobic cavities of the rHSA trimer and tetramer, respectively, producing huge artificial hemoproteins. These albumin–heme clusters can reversibly bind and release  $\text{O}_2$  under physiological conditions (37 °C, pH 7.3) and showed similar  $\text{O}_2$ -binding properties ( $\text{O}_2$ -binding affinity, association and dissociation rate constants) to those of the corresponding monomer. A large volume of  $\text{O}_2$  can be chemically dissolved into the albumin–heme cluster solutions relative to the monomeric rHSA-FeP when the molar concentration of the albumin scaffold is identical.

### Introduction

In our bloodstream, hydrophobic molecules of medium size (ex., long-chain fatty acids, bilirubin, steroids, hemin) are captured by human serum albumin (HSA, Mw: 66.5 kDa) and are allowed to circulate for a relatively long time to reach the disposal sites in the body.<sup>1</sup> The transporting ability of this shuttle protein contributes to maintaining the high concentration levels of the therapeutic drugs in the circulatory system.<sup>1,2</sup> Moreover, the albumin peptide exhibited a slow terminal clearance and catabolism, so that the conjugation of HSA with a therapeutic protein (ex., soluble CD4 and interferon- $\alpha$ ) provides clinical benefits in permitting less frequent administrations.<sup>3</sup> We have found that synthetic iron(II) porphyrins (hemes) were incorporated into the hydrophobic cavities of HSA, producing an albumin–heme hybrid, which can reversibly bind and release dioxygen ( $\text{O}_2$ ) under physiological conditions (pH 7.3, 37 °C).<sup>4</sup> This artificial hemoprotein has the capability to carry  $\text{O}_2$  like hemoglobin (Hb) or myoglobin (Mb) and functions as a red blood cell (RBC) substitute in vivo.<sup>5</sup>

One of the interesting characteristics of the HSA structure is the presence of a single reactive thiol of Cys-34.<sup>1,6</sup> The reaction of the bifunctional reagent, 1,6-bis(maleimido)-hexane (BMH), with HSA successfully creates an intermolecular covalent bridge between the two Cys-34s.<sup>7</sup> A total


of 16 molecules of synthetic heme were accommodated into the dimer and the obtained albumin–heme dimer solution is able to transport a large volume of  $\text{O}_2$  compared to the human blood ( $[\text{heme}] = 9.2 \text{ mM}$ ) while maintaining the colloid osmotic pressure on a physiological level.<sup>7b</sup> Another remarkable advantage of the HSA dimer is its long circulation persistence relative to the monomer, since the  $2\times$  size of the molecule could serve to remain in the blood vessel. We now extend this approach to produce the structurally defined albumin trimer and tetramer, namely “albumin clusters”. In this paper, we report, for the first time, the synthesis, physicochemical characterization, and preliminary pharmacokinetics of the albumin clusters cross-linked by *N*-succinimidyl-6-[3'-(2-pyridyldithio)propionamido]hexanoate (SPDPH), which efficiently connects an  $\text{NH}_2$  group of Lys and an SH group of Cys. The  $\text{O}_2$ -binding properties of the albumin–heme clusters incorporating the 2-[8-{*N*-(2-methylimidazolyl)octanoyloxymethyl}-5,10,15,20-tetrakis{ $\alpha,\alpha,\alpha,\alpha$ -*o*-(1-methylcyclohexanamido)phenyl}porphinatoiron(II) (FeP, Scheme 1), are also evaluated and compared to those of the corresponding monomer.

### Experimental Section

**Materials and Apparatus.** An rHSA (Albrec, 25 wt %) was provided from the NIPRO Corp (Osaka, Japan). Ethanol, dithiothreitol, and 2,2'-dithiopyridine (all high-purity grades) were purchased from Kanto Chemical Co., Inc. (Tokyo) and used without further purification. *N*-Succinimidyl-6-[3'-(2-pyridyldithio)propionamido]hexanoate (SPDPH) was

\* To whom correspondence should be addressed. Prof. Eishun Tsuchida, Ph.D. Tel: +81-3-5286-3120. Fax: +81-3-3205-4740. E-mail: eishun@waseda.jp (Eishun Tsuchida). E-mail: teruyuki@waseda.jp (Teruyuki Komatsu).

Scheme 1



purchased from Pierce Biotechnology (Rockford, USA). 2-[8-{*N*-(2-Methylimidazolyl)}octanoyloxymethyl]-5,10,15,20-tetrakis{ $\alpha,\alpha,\alpha,\alpha$ -*o*-(1-methylcyclohexanamido)-phenyl}porphinatoiron(II) (FeP) was prepared according to our previously reported procedure.<sup>8</sup>

**Synthesis of rHSA Clusters.** Ethanolic SPDPH (20 mM, 0.75 mL) was slowly added dropwise into the rHSA solution (0.75 mM, 2.0 mL) and gently stirred for 20 min at room temperature. The reaction mixture was diluted with phosphate-buffered saline (PBS, 10 mM, pH 7.4, 25 mL) and concentrated to 2.5 mL using an ADVANTEC UHP-76K ultrafiltration system with a Q0500 076E membrane (cutoff Mw 50 kDa). This washing was repeated three times to remove the excess SPDPH, affording 3'-(2-pyridyldithio)propionamido]hexanoated albumin (PDPH-rHSA, [rHSA] = 5.15 wt %, 2 mL). The albumin concentrations were normally measured by bromocresol green (BCG) methods using a Wako AlbuminB-Test.<sup>9</sup> The number of PDPH chains introduced into rHSA was determined by the assay of 2-thiopyridinone (2TP) with an absorption at 343 nm [molar absorption coefficient ( $\epsilon_{343}$ ):  $8.1 \times 10^3 \text{ M}^{-1}\text{cm}^{-1}$ ]. A 15-fold molar excess of dithiothreitol (DTT, 1 M, 1.35  $\mu\text{L}$ ) was added to the PBS solution of PDPH-rHSA (30  $\mu\text{M}$ ), and the formed 2-TP was quantitatively assayed after 10 min.

On the other hand, aqueous DTT (1.0 M, 56  $\mu\text{L}$ ) was added to the phosphate-buffered solution (pH 7.0, 10 mM) of rHSA (0.75 mM, 20 mL), and the solution was quickly mixed by a vortex mixer, followed by incubation for 30 min at room temperature. The resultant was washed three times with PBS the same as above, yielding a mercapto-albumin (SH-rHSA, 13 mL, [rHSA] = 7.77 wt %). The mercapto ratio of the Cys-34 was confirmed as 100% using the 2,2'-dithiopyridine (2,2'-DTP) procedure.<sup>10,11</sup>

The SH-rHSA solution was then added to the PDPH-rHSA, and the mixture was gently stirred for 20 h at room temperature. The Native-PAGEs were performed using an Amersham Biosciences Electrophoresis Power Supply EPS 301 with a PAG Mini Daiichi 2/15 (Daiichi Pure Chemicals, Co. Ltd.). The Native-PAGE pattern of the obtained reactant showed six bands including the unreacted SH-rHSA monomer. The HPLC measurement also demonstrated the formation of the rHSA clusters with a high molecular weight. The HPLC system consisted of a Shimadzu LC-8A pump and a Shimadzu SPD-10A UV detector. A Shodex Protein KW-803 column was used with PBS (pH 7.4) as the mobile phase

at 25 °C (1.0 mL min<sup>-1</sup>). Peak fitting of the elution curve was done using a Hulincks PeakFit program.

The rHSA clusters were purified by gel column chromatography using a BIO-RAD EGP Combo Rec system with Superdex 200pg (Pharmacia Corp., 5 cm $\phi$   $\times$  40 cm) and PBS (pH 7.4) as the mobile phase (3.5 mL min<sup>-1</sup>). The eluant was monitored at 280 nm and fractionated by a BIO-RAD model 2110 collector. The fraction showing the single bands for band C and D in the Native-PAGE was then carefully collected. The matrix associated laser desorption/ionization time-of-flight mass spectra (MALDI-TOF-MS) were obtained using a Shimadzu AXIMA-CFR Compact MALDI. The 10 mg mL<sup>-1</sup> sinapinic acid in 40% aqueous CH<sub>3</sub>CN was used as a matrix. The purity of the each component was checked by the HPLC measurement. The obtained yield was 10% for the rHSA trimer (band C) and 7% for the rHSA tetramer (band D).

**Physicochemical Properties.** The UV-vis absorption spectra were recorded on a JASCO V-570 spectrophotometer. The measurements were normally performed at 25 °C. Circular dichroism (CD) spectra were obtained using a JASCO J-725 spectropolarimeter. The concentration of the rHSA sample was 2  $\mu\text{M}$  in PBS, and quartz cuvettes with a 1.0-mm thickness were used for the measurements over the range of 195–250 nm.


**Transmission Electron Microscopy (TEM).** An aqueous solution of the albumin cluster was mixed with 2% phosphotungstic acid (pH 7), and the droplet was placed onto a 200 mesh carbon-coated copper grid, which was hydrophilized by a JEOL HDT-400 hydrophilic treatment device prior to use. The grid was allowed to air-dry and observed in a JEOL JEM-1011 electron microscope at an accelerating voltage of 100 kV.

**Circulation Lifetime in Vivo.** The 125-Iodinated rHSA tetramer was prepared by our previously reported procedures.<sup>7b</sup> The recovered <sup>125</sup>I-albumin had a specific activity of 24.3 MBq mg<sup>-1</sup> and was diluted by nonlabeled albumin tetramer before administration into anesthetized Wistar rats (ca. 250 g, male). The kinetics of the albumin clearance from the circulation was monitored by measuring the radioactivity in the plasma phase of blood taken from the lateral tail veins using an Aloka ARC 2000 Autowell Gamma Counter. Acid precipitability of the recovered radioactivity was confirmed by the TCA method.<sup>7b,12</sup> The rats were sacrificed 8 days after the sample injection by hemorrhage. The radioactivity of the excised organs was also measured. The care and handling of the animals were in accordance with NIH guidelines.

**Preparation of Albumin-Heme Clusters.** The preparations of albumin-heme clusters (rHSA-FeP trimer and tetramer) were carried out by mixing the EtOH solution of carbonyl-FeP and an aqueous phosphate-buffered solution of albumin clusters according to our previously reported procedures ([FeP]/[rHSA] = 26/1 or 34/1 (mol/mol)).<sup>4a,7b,8</sup> The albumin concentrations were measured using the CD spectra, and the amount of FeP was determined by the assay of the iron ion concentration using inductively coupled plasma spectrometry (ICP) with a Seiko Instruments SPS 7000A spectrometer.

**Magnetic Circular Dichroism (MCD).** MCD spectra for the phosphate-buffered solution of the albumin–heme clusters (10  $\mu\text{M}$ ) under  $\text{N}_2$ ,  $\text{CO}$ , and  $\text{O}_2$  atmospheres were measured using a JASCO J-820 circular dichrometer fitted with a 1.5 T electromagnet. The CD spectra at 0 T were always used as a baseline for each condition.

**$\text{O}_2$ -Binding Equilibrium and Kinetics.**  $\text{O}_2$  binding to FeP was expressed by eq 1:



The  $\text{O}_2$ -binding affinity (gaseous pressure at half  $\text{O}_2$  binding for heme,  $P_{1/2} = 1/K$ ) was determined by UV–vis absorption spectral changes at various  $\text{O}_2$  partial pressure.<sup>4b,8,13</sup> The appropriate  $\text{O}_2/\text{N}_2$  gas mixture ( $P_{\text{O}_2}$ : 0, 10, 20, 30, 80, 160, and 760 Torr) was prepared by a KOFLOC Gasblender GB-3C, and each spectrum was measured after flowing the gas for 15 min at 25 or 37  $^\circ\text{C}$ . FeP concentrations of 20  $\mu\text{M}$  were normally used for the measurements in the range of 350–700 nm. The  $\text{O}_2$ -binding constant ( $K$ ) was then calculated from the difference of the absorbance at 444 nm using Drago's equation.<sup>4b,8</sup> The half-lifetimes of the dioxygenated species of the albumin–heme clusters were determined by the time dependence of the absorption intensity for the  $\text{O}_2$ -adduct complex (549 nm).

The association and dissociation rate constants for  $\text{O}_2$  ( $k_{\text{on}}$  and  $k_{\text{off}}$ ) were measured by a competitive rebinding technique using a Unisoku TSP-1000WK–WIN time-resolved spectrophotometer with a Spectron Laser Systems SL803G-10 Q-switched Nd:YAG laser, which generated a second-harmonic (532 nm) pulse of 6-ns duration (10 Hz). A 150 W xenon arc-lamp was used as the monitor light source. The concentration of the albumin–heme cluster was normally 20  $\mu\text{M}$  and experiments were carried out at 25  $^\circ\text{C}$ . The absorption decays accompanying the  $\text{O}_2$  association obeyed three-component kinetics. We employed triple-exponentials equation to analyze the absorption decays;  $\Delta A(t)^{4c}$


$$\Delta A(t) = C_1 \exp(-k_1 t) + C_2 \exp(-k_2 t) + C_3 \exp(-k_3 t) \quad (2)$$

where  $k_1$ ,  $k_2$ , and  $k_3$  are apparent rate constants for the each components.


**$\text{O}_2$ -Concentration Measurements.** The chemically dissolved  $\text{O}_2$  in albumin–heme cluster solution was measured using an Ocean Photonics FOXY2000 Fiber Optic Oxygen Sensor with a USB2000 multichannels monochromator and FOXY-AL300 fiber optic sensor (Tokyo). This apparatus uses the fluorescence of a ruthenium complex to measure the partial pressure of  $\text{O}_2$ . The addition of 0.1 mL of CO to the phosphate-buffered solution of the dioxygenated rHSA–FeP cluster or monomer ( $[\text{FeP}]$ : 50  $\mu\text{M}$ , 2.0 mL,  $[\text{O}_2]$ : 700 Torr) in the closed tube immediately dissociates the coordinated  $\text{O}_2$  from FeP and increases the dissolved  $\text{O}_2$  content in the aqueous phase.

## Results and Discussion

**Synthesis and Characterization of rHSA Clusters.** We have shown that covalent cross-linking a unique Cys-34 of rHSA with BMH provided a defined rHSA dimer, in which




**Figure 1.** Synthetic scheme of albumin clusters with SPDPH.



**Figure 2.** Native-PAGE electrophoresis and HPLC elution curve of the reaction mixture at 25  $^\circ\text{C}$ . In the Native-PAGE pattern, lane a, protein ladder; lane b, the reaction mixture (band A: rHSA monomer). The HPLC profile was simulated by a six-components model using a PeakFit (the dotted line, the sum of the simulated six components; peak 1, rHSA monomer).

the essential structures of the rHSA unit are intact.<sup>7b</sup> We now extend this approach to produce albumin clusters. Our first attempt to connect the Cys-34 of rHSAs by multi-armed maleimido(polyoxyethylene) unfortunately failed. The maleimido-terminate at the polyoxyethylene chains are likely to be too flexible to react with the small thiol on the large rHSA molecule to make albumin clusters. On the other hand, *N*-succinimidyl-6-[3'-(2-pyridylidithio)propionamido]hexanoate (SPDPH) was successfully connected to an  $\text{NH}_2$  group of Lys and an SH group of Cys on the protein surface. Since rHSA contains 59 Lys in the globular structure, mixing a small molar excess SPDPH with rHSA immediately produced a 6-[3'-(2-pyridylidithio)propionamido]hexanoated rHSA (PDPH–rHSA; Figure 1). Assay of the pyridylidithio residues revealed that approximately 8.3 chains of PDPH were introduced into one rHSA molecule. The PDPH–rHSA acts as a core albumin for the next reaction.

Dithiothreitol (DTT) selectively reduces the mixed-disulfide of Cys-34<sup>10,11</sup> producing a mercapto–rHSA (SH–rHSA) as a shell albumin. After removing DTT, SH–rHSA was slowly dropwise added to the PDPH–rHSA and stirred for 20 h at room temperature (Figure 1). Native-PAGE of the reactant showed six distinct migration bands (Figure 2 inset, lane b: A–F, band A: SH–rHSA). On the basis of the



**Figure 3.** Native-PAGE electrophoresis and HPLC elution curves of the isolated rHSA clusters at 25 °C. In the Native-PAGE pattern, lane a, reaction mixture before purification; lane b, isolated band C; lane c, isolated band D. In the HPLC profiles, red line, rHSA monomer; orange line, rHSA dimer bridged through Cys-34 by BMH; blue line, isolated band C, which corresponds to the rHSA trimer; green line, isolated band D, which corresponds to the rHSA tetramer.


**Table 1.** Molecular Masses and *pI* Values of rHSA Monomer, Dimer, and Clusters

	$M_w$		<i>pI</i>
	obs. <sup>a</sup>	calcd.	
rHSA <sup>b</sup>	66331	66451	4.8
rHSA dimer <sup>b,c</sup>	132 741	133 180	4.8
band C (rHSA trimer)	200 469	201 614	4.8
band D (rHSA tetramer)	266 538	267 953	4.8

<sup>a</sup> Measured by MALDI-TOF-MS. <sup>b</sup> From ref 7b. <sup>c</sup> rHSA dimer bridged Cys-34 by BMH.

comparison with the protein ladder (lane a), the molecular weights of the bands B, C, and D were estimated to be ca. 130, 200, and 260 kDa, respectively. It can be postulated that they are the rHSA dimer, trimer, and tetramer. The pyridyldithio terminates of the core albumin reacted with the single active Cys-34 of the shell albumin creating albumin clusters. The HPLC profile of the reaction mixture exhibited broad multiple bands in the range of 6.5–8.5 min before the rHSA peak (9.0 min; Figure 2). From the careful inspection of the elution curve by peak fitting simulation, we could divide the entire pattern into six components (peaks 1–6). Most probably, the peaks 2–6 correspond to the rHSA dimer to hexamer. Gel permeation chromatography also showed a similar elution curve. Several synthesis repetitions always gave the same patterns in Native-PAGE, HPLC, and GPC. The fractions whose Native-PAGE showed bands C and D were then corrected (Figure 3, inset lanes b and c). Their HPLC profiles exhibited a sharp peak at the exactly the same position where we predicted for peaks 3 and 4 in Figure 2.

The MALDI-TOF-MS of the components of peaks 3 (band C) and 4 (band D) showed a molecular masses at *m/z* 200 469 and 266 538, respectively, which are in good agreement with the calculated value of the rHSA trimer and tetramer ( $M_w = 201 614$  and  $267 953$ ) within a difference of 0.5% (Table 1). We first isolated the well-defined rHSA trimer and tetramer in which the Lys groups of the core



**Figure 4.** CD spectra of rHSA monomer, dimer bridged through Cys-34 by BMH and clusters in PBS solution (pH 7.4) at 25 °C.

albumin are covalently bridged by the Cys-34 group of the shell albumins.


The peak area evaluations for the six components in Figure 2 indicated their molar ratios in the reaction mixture; monomer (88.2%), dimer (3.1%), trimer (4.3%), tetramer (2.5%), pentamer (1.4%), and hexamer (0.5%). Because the average degree of polymerization was 3.3, we estimated the reaction ratio (*X*) of the PDPH-rHSA

$$\text{reacted PDPH-rHSA}:\text{unreacted (PDPH-rHSA + SH-rHSA)} = X:(1 - X) + (10 - 2.3X) = 11.8:88.2 \quad (3)$$


Thus, *X* was calculated to be 1.0; this means that all of the PDPH-rHSA (core albumin) participated in the reaction with the shell albumin. The formation ratio of each cluster can be estimated; dimer (26%), trimer (36%), tetramer (22%), pentamer (12%), and hexamer (4%).

The CD spectral patterns ( $\lambda_{\text{min}} = 208$  and 222 nm) and the molar ellipticities at 208 and 222 nm ( $[\theta]_{208} = 1.9 \times 10^4$  deg cm<sup>2</sup> dmol<sup>-1</sup>,  $[\theta]_{222} = 1.8 \times 10^4$  deg cm<sup>2</sup> dmol<sup>-1</sup>) of the isolated rHSA trimer and tetramer were identical to those of the monomer and dimer (Figure 4).<sup>4b,7b</sup> Their isoelectric points (*pI* = 4.8) were also identical to that of rHSA (Table 1). These results implied that the secondary/tertiary structure, the  $\alpha$ -helix content, and surface net charges of the rHSA units were intact after the cluster formation.

TEM of the negatively stained samples of the rHSA tetramer showed homogeneous particles with a diameter of 20–30 nm (Figure 5a,b). The appearance of the cluster solutions was unchanged for over one year and underwent no aggregation and precipitation. We postulate that one tetramer consists of four rHSA molecules bound in the trigonal pyramid form, which was drawn as a model in Figure 5c. rHSA involves a total of 59 Lys groups, and the cross-linker SPDPH can statistically bind to the surface. On the basis of the assay of the dithiopyridyl group, we found that the 8.3 functional PDPH arms are introduced into the core albumin. The shell albumins (SH-rHSAs) therefore approach the PDPH-rHSA from all directions to form a disulfide bridge with Cys-34. As a consequence, the conformation of the tetramer should become a trigonal pyramid-like structure, which is the most favorable arrangement to avoid the steric repulsion of the albumin units.




**Figure 5.** TEM observations of negatively stained rHSA tetramer. In panels a and c, the scale bars indicate the length of 30 nm. In panel c, the trigonal pyramid form of the rHSA tetramer is predicted from the one molecule under magnification.



**Figure 6.** Plasma levels of  $^{125}\text{I}$ -rHSA tetramer after intravenously administration to Wistar rats (rHSA amount =  $1.0 \text{ mg kg}^{-1}$ ). The data for the  $^{125}\text{I}$ -rHSA monomer and dimer were cited from our previously reported paper (ref 7b). All values are mean  $\pm$  S. D. ( $n = 3$ ).

**Circulation Lifetime of  $^{125}\text{I}$ -Labeled rHSA Tetramer in Rats.** The rHSA tetramer labeled with  $^{125}\text{I}$  was injected into anesthetized rats to determine the blood circulation lifetimes. Throughout the experiments, the turbidity of the plasma phase and the blood cell numbers were constant, showing no aggregation of the albumin clusters and blood cell components. The time courses of the radioactivity demonstrated two-phase kinetics and significant differences from the monomer's decay (Figure 6). The half-lifetime ( $\tau_{1/2}$ , time when the initial value decreased to 50%) of the rHSA tetramer was 5.5 h, which was 2.4-fold longer than that of the monomer (2.3 h).<sup>7b</sup> This was due to the low ratio of the distribution phase ( $\alpha$ -phase) of the tetramer (26%), compared to the monomer and dimer, 39% and 36%, respectively. The increase in the molecular size led to retardation of the extravasation through the vascular endothelium. On the contrary, its lifetime ( $\tau$ ) of the disappearance phase ( $\beta$ -phase; 8.9 h) was shorter than the tightly bridged rHSA dimer with a sulfide bond (16.2 h); although the  $\tau_{1/2}$  of the dimer is lower than the tetramer, there is a greater amount of dimer at 24 h than tetramer. The rHSA tetramer disappeared slowly after 12 h, and 10% remained at 24 h from the injection, which was almost the same amount observed in the monomer group. After 12 h, the weak disulfide bonds between the core and shell albumins may be cleaved to dissociate the monomer




**Figure 7.** UV-vis absorption spectral changes of the rHSA-FeP tetramer in phosphate-buffered solution (pH 7.3) at various conditions (25 °C).


components and cleared from the bloodstream. Radioactivity of the trichloroacetic acid precipitates recovered up to 90% of the intensity, which means  $^{125}\text{I}$  did not dissociate from the proteins. The tissue distributions of the rHSA tetramer were in the skin, liver, and spleen, and there were no differences to that of the rHSA monomer. Our albumin tetramer may become a unique vehicle which serves to sustain a high drug concentration particularly during the initial phase.

**Albumin-Heme Clusters and Their  $\text{O}_2$  Binding.** Mixing the ethanolic FeP with an aqueous albumin cluster and removing the ethanol by ultrafiltration produced red-colored homogeneous albumin-heme cluster solutions. They were rather stable and stored for more than 1 year at 4 °C without any precipitation. From the quantitative assays of rHSA and FeP, the molar ratios of the FeP/rHSA were determined to be 24.2 and 31.6 for the trimer and tetramer, which are 3- and 4-fold molar excess amounts of the monomeric rHSA-FeP. We can conclude that a maximum of eight FePs were also incorporated into the rHSA unit. These albumin-heme clusters showed identical CD spectra and  $pI$  values (4.8) with the original rHSA trimer and tetramer, which implied that the FeP incorporation did not cause any structural changes in the albumin components.

The UV-vis absorption spectrum of the aqueous rHSA-FeP tetramer in an  $\text{N}_2$  atmosphere showed the formation of a five-coordinate high-spin complex involving an axially bound 2-methylimidazolyl side-chain ( $\lambda_{\text{max}} = 444, 539, \text{ and } 565 \text{ nm}$ ; Figure 7).<sup>4b,8,13</sup> After this solution was kept under a stream of  $\text{O}_2$  for 5 min, the absorption spectra changed to that of a typical  $\text{O}_2$ -adduct complex ( $\lambda_{\text{max}} = 426 \text{ and } 549 \text{ nm}$ ).<sup>4b,8,13</sup> This dioxygenation was reversibly observed and dependent on the  $\text{O}_2/\text{N}_2$  pressure under physiological conditions (pH 7.3, 37 °C). After admitting the  $\text{CO}$  gas, the  $\text{O}_2$ -adduct complex immediately moved to the carbonyl low-spin complex ( $\lambda_{\text{max}} = 427 \text{ and } 539 \text{ nm}$ ). The rHSA-FeP trimer also showed identical spectral changes under these conditions [rHSA-FeP trimer in  $\text{N}_2$  ( $\lambda_{\text{max}} = 442, 539, \text{ and } 564 \text{ nm}$ ),  $\text{O}_2$  ( $\lambda_{\text{max}} = 423 \text{ and } 547 \text{ nm}$ ), and  $\text{CO}$  atmosphere ( $\lambda_{\text{max}} = 426 \text{ and } 534 \text{ nm}$ )].



**Figure 8.** MCD spectral changes of the rHSA-FeP tetramer in phosphate-buffered solution (pH 7.3) at various conditions (25 °C).



**Figure 9.** Absorption decay of O<sub>2</sub> rebinding to the rHSA-FeP cluster in phosphate-buffered solution (pH 7.3) after the laser flash photolysis at 25 °C. The kinetics was composed of three phases and relaxation curve was fitted by triple-exponentials.

MCD spectroscopy revealed the coordination structure of the FeP in the rHSA clusters. Under an N<sub>2</sub> atmosphere, the MCD of the rHSA-FeP tetramer resembled the well-characterized spectrum of a mono-imidazole ligated five-*N*-coordinate high-spin tetraphenylporphyratoiron(II) (Figure 8).<sup>14</sup> This observation indicates that the amino acid residue in the rHSA structure did not bind to the sixth position of FeP. The admission of O<sub>2</sub> gas changed the spectrum to an S-shaped A-term MCD in the Soret-band region, which shows the formation of an O<sub>2</sub>-adduct complex.<sup>14</sup> The CO adduct is also low spin and exhibited a similar A-term MCD band with a high intensity.


The autoxidation reaction of the oxy state ( $\lambda_{\text{max}} = 549$  nm) slowly occurred and the absorption intensity of 549 nm almost disappeared after 48 h, leading to the formation of the inactive Fe(III)P. The half-lives of the dioxygenated species ( $\tau_{1/2}$ ) of the rHSA-FeP trimer and tetramer were both 7 h at 37 °C, which are almost the same as that of our previous results for the rHSA-FeP dimer ( $\tau_{1/2} = 6$  h).<sup>7b</sup>

**O<sub>2</sub>-Binding Kinetics and Equilibrium of Albumin-Heme Clusters.** Flash photolysis experiments for the albumin-heme clusters were performed to determine the asso-

**Table 2.** O<sub>2</sub>-Binding Parameters of rHSA-FeP Monomer, Dimer, and Clusters in Phosphate-Buffered Solution (pH 7.3) at 25 °C

	10 <sup>-6</sup> <i>k</i> <sub>on</sub> (M <sup>-1</sup> s <sup>-1</sup> )	10 <sup>-6</sup> <i>K</i> <sub>on</sub> (M <sup>-1</sup> s <sup>-1</sup> )	10 <sup>-2</sup> <i>k</i> <sub>off</sub> (s <sup>-1</sup> )	10 <sup>-2</sup> <i>K</i> <sub>off</sub> (s <sup>-1</sup> )	<i>P</i> <sub>1/2</sub> (Torr) <sup>a</sup>
rHSA-FeP <sup>b</sup>	46	7.3	9.8	1.6	13 (35)
rHSA-FeP dimer <sup>c</sup>	28	4.8	6.7	1.2	15 (38)
rHSA-FeP trimer	46	5.9	8.7	1.1	12 (38)
rHSA-FeP tetramer	53	13	11	2.7	12 (38)
Hb(T-state) $\alpha^d$	2.9		1.8		40
human RBC <sup>e</sup>					8 (27)

<sup>a</sup> At 37 °C in parenthesis. <sup>b</sup> From ref 8. <sup>c</sup> From ref 7b. <sup>d</sup> Hb $\alpha$  chain (monomer), aqueous pH 7.0–7.4, 20 °C, from ref 16. <sup>e</sup> From ref 17.



**Figure 10.** Molar ratio of the increased O<sub>2</sub> per rHSA cluster (mol/mol) after exposure of CO gas to rHSA-FeP cluster solutions (25 °C).

ciation and dissociation rate constants of O<sub>2</sub> (*k*<sub>on</sub>, *k*<sub>off</sub>). We have shown that the O<sub>2</sub> associations to FePs in the monomeric rHSA are affected by the molecular environments around the FeP site, for example, steric hindrance of the nearest amino acid residues.<sup>4c</sup> In the case of the albumin-heme clusters, there should be multiple kinetic parameters. Nevertheless, the O<sub>2</sub> binding profile to FeP demonstrated the same trends as the rHSA-FeP monomer. The absorption change accompanying the O<sub>2</sub> recombination clearly obeyed three-phases, which were fit by a triple-exponential kinetics (Figure 9). The fastest minor component (*k*<sub>1</sub>) is related to a base dissociation reaction.<sup>15</sup> The linear relationship between the apparent rates *k*<sub>2</sub> and *k*<sub>3</sub> vs the [O<sub>2</sub>] provided two association rate constants for the fast O<sub>2</sub> rebinding (*k*<sub>on</sub>) and the slow O<sub>2</sub> rebinding (*k*'<sub>on</sub>; Table 2). The *k*<sub>on</sub> values are 4.1–7.8-fold greater than *k*'<sub>on</sub>, and the amplitude ratios of the fast and slow phases were approximately 1/1, which implied that half of the FeP molecules in the rHSA trimer and tetramer may locate in the slow sites for the O<sub>2</sub> association. The O<sub>2</sub>-binding affinity (*P*<sub>1/2</sub>) of the rHSA-FeP clusters were determined to be 38 Torr at 37 °C on the basis of the UV-vis absorption spectral changes by O<sub>2</sub> titration with different [O<sub>2</sub>].<sup>4b,8,13</sup> The obtained *P*<sub>1/2</sub> is close to that of the rHSA-FeP monomer and human RBC (Table 2).<sup>8,16,17</sup> The cluster formation did not alter the O<sub>2</sub>-binding properties of rHSA-FeP.

**O<sub>2</sub> Concentration in Albumin–Heme Cluster Solution.**

The addition of small amounts of CO to the aqueous solutions of the dioxygenated rHSA–FeP clusters ([FeP] = 50  $\mu$ M) in closed tubes dissociates the coordinated O<sub>2</sub>, which immediately diffuses in the medium. In all cases, the O<sub>2</sub> concentrations increased 0.05 mM after the CO exposure. The UV–vis absorption spectra of the solutions changed to that of the carbonyl complex. The molar ratio of the chemically bound O<sub>2</sub> per albumin vehicle ([rHSA cluster] or [rHSA]) (mol/mol) showed that the albumin–heme clusters bind a large volume of O<sub>2</sub> relative to the monomer (Figure 10). The rHSA–FeP tetramer solution ([rHSA tetramer] = 0.75 mM, [heme] = 24 mM) could probably transport a 2.6-fold greater volume of O<sub>2</sub> compared to human blood ([heme] = 9.2 mM) while maintaining the colloid osmotic pressure on a physiological level.

**Conclusions**

The structurally defined albumin clusters prepared using a unique SH group of Cys-34 reported here provide the following characteristics.

(i) Essential properties of the rHSA units (the secondary/tertiary structure, surface net charges) were intact after the cluster formation. Our albumin clusters behave as a gigantic serum albumin.

(ii) The tetramer showed a longer half-life (5.5 h) in the bloodstream of rats compared to that of the monomer due to the low ratio of the  $\alpha$ -phase (26%). However, it slowly disappeared after 12 h and was 10% of the basal value at 24 h after the injection.

(iii) The rHSA unit in the clusters can incorporate a maximum of eight FeP molecules, that is, the trimer and tetramer contain 24 and 32 active O<sub>2</sub>-binding heme sites, which are 6- and 8-fold greater than that of the native tetrameric Hb, respectively. The obtained albumin–heme clusters become huge artificial hemoproteins with molecular weights of 235 and 313 kDa and can reversibly bind O<sub>2</sub> under physiological conditions.

(iv) The albumin–heme tetramer has the capability to transport a 4-fold larger volume of O<sub>2</sub> compared to the corresponding monomer when the albumin vehicle molar concentrations were identical. It implies that the albumin–heme clusters potentially become novel RBC substitutes having a 2.6-fold higher O<sub>2</sub> transporting ability than human blood.

This method of creating albumin clusters should lead to generating defined protein polymers and a new series of

functional biomaterials. The preparations of the starburst rHSA dendrimer and linear string of rHSA pearls are now in progress.

**Acknowledgment.** This work was partially supported by a Grant-in-Aid for Scientific Research (No. 16350093) from JSPS, and a Grant-in-Aid for Exploratory Research (No. 16655049) from MEXT Japan, and a Health Science Research Grant (Regulatory Science, B5-551) from MHLW Japan. Prof. Dr. Koichi Kobayashi (Keio University) and Mr. Hisashi Yamamoto (NIPRO Corp.) are greatly acknowledged for the animal experiments.

**References and Notes**

- (1) Peters, T., Jr. *All about albumin, biochemistry, genetics, and medical applications*; Academic Press: San Diego, CA, 1997; and reference therein.
- (2) (a) Kragh-Hansen, U. *Pharmacol. Rev.* **1981**, *33*, 17–53. (b) Kragh-Hansen, U. *Danish Med. Bull.* **1990**, *37*, 57–84.
- (3) Sheffield, W. P. *Curr. Drug Targets Cardiovasc. Haematol. Disord.* **2001**, *1*, 1–22.
- (4) (a) Komatsu, T.; Hamamatsu, K.; Wu, J.; Tsuchida, E. *Bioconjugate Chem.* **1999**, *10*, 82–86. (b) Tsuchida, E.; Komatsu, T.; Matsukawa, Y.; Hamamatsu, K.; Wu, J. *Bioconjugate Chem.* **1999**, *10*, 797–802. (c) Komatsu, T.; Matsukawa, Y.; Tsuchida, E. *Bioconjugate Chem.* **2000**, *11*, 772–776.
- (5) Tsuchida, E.; Komatsu, T.; Matsukawa, Y.; Nakagawa, A.; Sakai, H.; Kobayashi, K.; Suematsu, M. *J. Biomed. Mater. Res.* **2003**, *64A*, 257–261.
- (6) Carter, D. C.; Ho, J. X. *Adv. Protein Chem.* **1994**, *45*, 153–203.
- (7) (a) Komatsu, T.; Hamamatsu, K.; Tsuchida, E. *Macromolecules* **1999**, *32*, 8388–8391. (b) Komatsu, T.; Oguro, Y.; Teramura, Y.; Takeoka, S.; Okai, J.; Anraku, M.; Otagiri, M.; Tsuchida, E. *Biochim. Biophys. Acta* **2004**, *1675*, 21–31.
- (8) Komatsu, T.; Matsukawa, Y.; Tsuchida, E. *Bioconjugate Chem.* **2002**, *13*, 397–402.
- (9) Dumas, B. T.; Watson, W. A.; Biggs, H. G. *Clin. Chim. Acta* **1971**, *31*, 87–96.
- (10) Grassetti, D. R.; Murray, J. F., Jr. *Arch. Biochem. Biophys.* **1967**, *119*, 41–49.
- (11) Pedersen, A. O.; Jacobsen, J. *Eur. J. Biochem.* **1980**, *106*, 291–295.
- (12) Watanabe, H.; Yamasaki, K.; Kragh-Hansen, U.; Tanase, S.; Harada, K.; Suenaga, A.; Otagiri, M. *Pharm. Res.* **2001**, *18*, 1775–1781.
- (13) Collman, J. P.; Brauman, J. I.; Iverson, B. L.; Sessler, J. L.; Morris, R. M.; Gibson, Q. H. *J. Am. Chem. Soc.* **1983**, *105*, 3052–3064.
- (14) (a) Collman, J. P.; Brauman, J. I.; Doxsee, K. M.; Halbert, T. R.; Bunnberg, E.; Linder, R. E.; LaMar, G. N.; Guadio, J. D.; Lang, G.; Spartialian, K. *J. Am. Chem. Soc.* **1980**, *102*, 4182–4192. (b) Collman, J. P.; Basolo, F.; Bunnberg, E.; Collins, T. C.; Dawson, J. H.; Ellis, P. E., Jr.; Marrocco, M. L.; Moscovitz, A.; Sessler, J. L.; Szymanski, T. *J. Am. Chem. Soc.* **1981**, *103*, 5636–5648.
- (15) Geibel, J.; Cannon, J.; Campbell, D.; Traylor, T. G. *J. Am. Chem. Soc.* **1978**, *100*, 3575–3585.
- (16) Sawicki, C. A.; Gibson, Q. H. *J. Biol. Chem. Soc.* **1977**, *252*, 7538–7547.
- (17) Severinghaus, J. W. *J. Appl. Physiol.* **1966**, *21*, 1108–1116.

BM050454U

## Human Serum Albumin Hybrid Incorporating Tailed Porphyrinatoiron(II) in the $\alpha,\alpha,\alpha,\beta$ -Conformer as an $O_2$ -Binding Site

Akito Nakagawa, Teruyuki Komatsu,\* Makoto Iizuka, and Eishun Tsuchida\*


Advanced Research Institute for Science and Engineering, Waseda University, 3-4-1 Okubo, Shinjuku-ku, Tokyo 169-8555 Japan. Received June 1, 2005; Revised Manuscript Received October 30, 2005

We have found that recombinant human serum albumin (HSA) incorporating tailed porphyrinatoiron(II) in the  $\alpha,\alpha,\alpha,\beta$ -conformer can reversibly bind and release  $O_2$  under physiological conditions (pH 7.3, 37 °C) like hemoglobin and myoglobin.  $\beta$ -2-Methylimidazolyl-tailed porphyrinatoirons (**6a**, **6b**) are synthesized via four steps from the atropisomers of tetrakis(*o*-aminophenyl)porphyrin. The stereochemistry of the  $\alpha,\alpha,\alpha,\beta$ -conformer has been determined by NMR spectroscopy. **6a** and **6b** form stable  $O_2$ -adduct complexes in toluene solution at room temperature. The association rate constants of  $O_2$  are 3.1- and 1.9-fold lower than those of the corresponding  $\alpha,\alpha,\alpha,\alpha$ -conformers (**1a**, **1b**), indicating that the three substituents (cyclohexanamide or pivalamide groups) are close to each other on the porphyrin platform and construct a narrow encumbrance around the  $O_2$ -coordination site. Although **6a** and **6b** are incorporated into the hydrophobic domains of HSA to produce the albumin–heme hybrid, only HSA-**6a** can bind  $O_2$  in aqueous medium. The cyclohexanamide fences are necessary for the tailed porphyrinatoiron to form a stable  $O_2$ -adduct complex under physiological conditions. The  $O_2$ -binding affinity ( $P_{1/2}$ ) of HSA-**6a** is 45 Torr (37 °C), and the  $O_2$  transporting efficiency between lungs and muscle tissues in the human body is estimated to be identical to that of human red blood cells. The HSA-**6a** solution will become one of the most promising materials for red blood cell substitutes, which can be manufactured on an industrial scale.

### INTRODUCTION

To reproduce the  $O_2$ -binding ability of hemoglobin (Hb) and myoglobin (Mb), numerous numbers of model hemes have been synthesized over the past decades (1). These continuous approaches, aimed at understanding the precise mechanism of the  $O_2$ -binding reaction, have been mostly accomplished in organic solvents, and tetrakis(phenyl)porphyrin (TPP) was widely used as a molecular scaffold. We have also synthesized tetrakis- $\{\alpha,\alpha,\alpha,\alpha$ -*o*-(1-methylcyclohexanamido)phenyl\}porphyrinatoiron(II) bearing a covalently linked proximal imidazole (**1a**, Figure 1)<sup>1</sup> that forms a stable  $O_2$ -adduct complex in toluene solution at ambient temperature (2). The four cyclohexanamide fences on the distal-side ( $\alpha$ -side) of the porphyrin plane are bulky enough to prevent  $\mu$ -oxo dimer formation, and the 2-methylimidazolyl arm intramolecularly coordinated to the  $Fe^{2+}$  center from the proximal-side ( $\beta$ -side) modulates the  $O_2$ -binding affinity.

Some substantial efforts have been directed to prepare an artificial  $O_2$  carrier involving a synthetic heme under physiological conditions (pH 7.3, 37 °C), which may become a red blood cell substitute (1a, 3). We have successfully incorporated **1a** into the hydrophobic domains of recombinant human serum albumin (HSA) and found that the albumin–heme hybrid (HSA-**1a**) could reversibly absorb  $O_2$  in aqueous medium (1a, 2, 4). This red-colored albumin solution showed a long shelf life of over two years without precipitation. More recently,



**Figure 1.** Structures of porphyrinatoiron derivatives in the  $\alpha,\alpha,\alpha,\alpha$ -conformer and  $\alpha,\alpha,\alpha,\beta$ -conformer (tailed porphyrinatoiron).

exchange transfusion experiments with HSA-**1a** into anesthetized rats demonstrated that it effectively rescitates the hemorrhagic shock state and transports  $O_2$  to the muscle tissues (5). We are now developing this albumin–heme hybrid as an entirely synthetic red blood cell substitute that can be extensively used in a variety of medical situations (6).

The only disadvantage of this synthetic heme **1a** is that a great deal of labor is required to make the  $\alpha,\alpha,\alpha,\alpha$  ( $\alpha^4$ )-conformer and to introduce the imidazolylalkyl arm at the porphyrin periphery via the Vilsmeier reaction (2). The starting material, tetrakis( $\alpha,\alpha,\alpha,\alpha$ -*o*-aminophenyl)porphyrin (TAPP), is in a statistical mixture of the four possible atrop isomers ( $\alpha,\alpha,\alpha,\alpha$ ,  $\alpha,\alpha,\alpha,\beta$ ,  $\alpha,\beta,\alpha,\beta$ ,  $\alpha,\alpha,\beta,\beta$ ; the ratio is 1:4:2:1), and the variable  $\alpha^4$ -conformer used to be isolated by Lindsey's procedure with a silica gel column separation (7). The number of total steps for the synthesis of **1a** is, therefore, eight from TAPP.


In this study, we first incorporated a "tailed porphyrinatoiron" with the  $\alpha^3\beta$ -conformer as an  $O_2$ -binding site of the albumin–heme. A series of tailed porphyrins as the model compound of Hb and Mb were synthesized by Collman and co-worker (8). There are two advantages of the tailed porphyrin: (i) the statistical content of the  $\alpha^3\beta$ -conformer of TAPP is maximum

\* Corresponding authors: (E.T.) Tel: +81-3-5286-3120. Fax: +81-3-3205-4740. E-mail: eishun@waseda.jp. (T.K.) E-mail: teruyuki@waseda.jp.

<sup>1</sup> Abbreviations: **1a**: 2-[8-{*N*-(2-methyl-1-imidazolyl)octanoyloxy}-methyl]-5,10,15,20-tetrakis{ $\{\alpha,\alpha,\alpha,\alpha$ -*o*-(1-methylcyclohexanamido)phenyl\}porphyrinatoiron; **1b**: 2-[8-{*N*-(2-methyl-1-imidazolyl)octanoyl oxymethyl]-5,10,15,20-tetrakis{ $\{\alpha,\alpha,\alpha,\alpha$ -*o*-(pivalamido)phenyl\}porphyrinatoiron; **6a**: 5,10,15-Tris { $\{\alpha,\alpha,\alpha,\alpha$ -*o*-(1-methylcyclohexanamido)phenyl\}-20-mono[ $\beta$ -*o*-[6-{*N*-(2-methyl-1-imidazolyl)hexanamido]phenyl]-porphyrinatoiron; **6b**: 5,10,15-Tris( $\{\alpha,\alpha,\alpha,\alpha$ -*o*-(pivalamido)phenyl\}-20-mono[ $\beta$ -*o*-[6-{*N*-(2-methyl-1-imidazolyl)hexanamido]phenyl]-porphyrinatoiron.



Scheme 1. Synthesis of Tailed Porphyrinatoirons



(50%), and (ii) there is no need to modify the porphyrin ring because the proximal base is attached to the fourth  $\beta$ -*o*-NH<sub>2</sub> group of the phenyl ring. This convenient synthetic procedure is a great advantage for the industrial scale-up of the manufacturing of the albumin–heme solution. However, we were not certain of the stability of the O<sub>2</sub>-adduct complex of the tailed porphyrinatoiron(II) in an aqueous medium. It has been postulated that the four substituents were essential for preventing an unfavorable proton-driven oxidation of the central ferrous ion of the Fe<sup>2+</sup>TPP derivatives in water (1*a*, 3).

First, we describe the synthesis and stereochemistry of the 2-methylimidazole-tailed porphyrinatoirons (6*a*, 6*b*) and compare their O<sub>2</sub>-binding properties in toluene solution. The effects of the substituents on the O<sub>2</sub>-binding parameters are discussed. Furthermore, the O<sub>2</sub>-binding property of the albumin–heme hybrid including the tailed porphyrinatoiron(II) 6*a* has been characterized under physiological conditions. The 5 wt % albumin–heme solution involving the easily prepared 6*a* could be the most promising artificial O<sub>2</sub> carrier suitable for mass production.

## EXPERIMENTAL SECTION

**Synthesis of Tailed Porphyrinatoirons.** Experimental details of the synthesis and spectra (<sup>1</sup>H NMR, IR, UV–Vis, HR-MS) are supplied as Supporting Information.

**Reduction of Ferric Complex to Ferrous Complex in Toluene.** Reduction to the porphyrinatoiron(II) was carried out using toluene–aq Na<sub>2</sub>S<sub>2</sub>O<sub>4</sub> in a heterogeneous two-phase system under an N<sub>2</sub> atmosphere as previously reported (9). After separation of the two phases, the organic layer containing the ferrous complex was transferred to a 1-cm quartz cuvette under an N<sub>2</sub> atmosphere. The UV–Vis absorption spectra were recorded by a JASCO V-570 spectrophotometer.

**Preparation of Albumin–Heme Hybrid.** The HSA (Albrec, 25 wt %) was obtained from the NIPRO Corp. (Osaka). Aqueous ascorbic acid (15 mM, 20  $\mu$ L) was added to an ethanol solution of the porphyrinatoiron(III) derivative (37.5  $\mu$ M, 4 mL) under CO. After complete reduction of the central ferric ion, the UV–Vis absorption spectrum showed the formation of the six-coordinated carbonyl complex. This ethanol solution was slowly injected into the phosphate buffered solution (pH 7.3, 8 mL) of HSA (9.38  $\mu$ M) through a Teflon tube under a pressure of CO stream. The mixture was dialyzed using a cellulose membrane against phosphate buffer (pH 7.3) for 2 and 15 h at 4  $^{\circ}$ C. The ethanol concentration should be reduced to less than 100 ppm. Finally, the total volume was adjusted to 15 mL, thus producing the carbonyl albumin–heme solution (heme/HSA = 4 (mol/


mol), [Fe]: 20  $\mu$ M). The water was deionized using an ADVANTEC GS-200 system.

**O<sub>2</sub>-Coordination Equilibria and Kinetics.** The O<sub>2</sub>-binding affinity ( $P_{1/2}$ ) of the porphyrinatoiron(II) in organic solvents or their albumin–hemes in aqueous solution were determined by the spectral changes at various partial pressures of O<sub>2</sub> in previous reports (2, 10). The heme concentrations of 20  $\mu$ M were normally used for the UV–Vis absorption spectroscopy. The spectra were recorded within the range of 350–700 nm. The O<sub>2</sub>-association and -dissociation rate constants ( $k_{on}$ ,  $k_{off}$ ) were measured by a competitive rebinding technique (11, 12) using a Unisoku TSP-1000WK-WIN time-resolved spectrophotometer with a Spectron Laser system SL803G-10 Q-switched Nd:YAG laser, which generated a 532 nm pulse of 6-ns duration (10 Hz).

**Magnetic Circular Dichroism (MCD).** The MCD for the phosphate buffered solutions (pH 7.3) of HSA–6*a* (20  $\mu$ M) under N<sub>2</sub>, O<sub>2</sub>, and CO atmospheres were measured using a JASCO J-820 circular dichrometer fitted with a 1.5 T electromagnet at 25  $^{\circ}$ C. The accumulation times were normally five, and each spectra were subtracted by ones without the electromagnetic as a baseline.

## RESULTS AND DISCUSSION

**Synthesis of Tailed Porphyrinatoiron.** The tailed porphyrinatoirons, 6*a* and 6*b*, can be synthesized via four reaction steps from TAPP with 6- $\{N$ -(2-methyl-1-imidazolyl)hexanoic acid (Scheme 1), and their structures were determined by IR, UV, mass and NMR (<sup>1</sup>H NMR, H–H COSY, Nuclear Overhauser effect (NOE) experiment) spectroscopies. First, TAPP was monotritylated using tritylbromide at room temperature. Statistically, six atrop isomers of the monotritylated compound are formed. Collman and co-workers reported the superior synthesis of tris( $\alpha$ , $\alpha$ , $\alpha$ -aminophenyl)-mono( $\beta$ -tritylamino)phenylporphyrin (2) using the alumina absorption technique in the dark (13). We isolated two major components from the reaction mixture according to the procedure with the  $R_f$  values (chloroform/ethyl acetate = 1:1 (v:v)) of 0.75 (compound A) and 0.90 (compound B). The coupling reaction of compound A with pivaloyl chloride gave a single product, tris(pivalamido)phenyl-monotritylphenylporphyrin (compound A1). On the other hand, the same coupling reaction of compound B provided two products (compounds B1 and B2) with  $R_f$  values (chloroform/ethyl acetate = 2:1 (v/v)) of 0.68 and 0.62, respectively. The mass spectra of the above three compounds exactly demonstrated the same value (calcd. for C<sub>78</sub>H<sub>73</sub>N<sub>8</sub>O<sub>3</sub>: 1169.5806), indicating that A1, B1, and B2 are atrop isomers. In <sup>1</sup>H NMR spectra of A1 and B1, the peaks derived from the CH<sub>3</sub> protons in the pivalamide groups were

Scheme 2. Atropisomers of **2** and Their Pivalamide Derivatives

clearly separated into two peaks, and the patterns resembled those of the other  $\alpha^3\beta$ -structured TAPP derivatives (*14*, *15*) (see Figures ES11–ES13, Supporting Information). The differences in the chemical shift between the two peaks were 0.12 (**A1**) and 0.15 (**B1**) ppm, respectively. The CH<sub>3</sub> peaks of **B2** were also split, but the peak separation was rather small, 0.01 ppm.

To clarify the stereochemistry of these atrop isomers and the geometry of the substituents, we employed the NOE differential spectra (*16*) (see Figures ES11–ES13, Supporting Information). In porphyrin **A1**, three pivalamide groups are directed toward the same side and a trityl group is directed only toward the other side, which means **A1** is the target compound **3b**. In **B1**, one of the pivalamide groups is in the same plane with the trityl group, but they do not interact with each other. This result suggests the formation of the  $\alpha,\beta,\alpha,\beta$ -conformer **3'b**. In **B2**, at least one pivalamide group is on the same side with the trityl group. In this case, there are four atrop isomers expected, but we concluded **B2** would be the  $\alpha,\alpha,\beta,\beta$ -structure (**3''b**) because the parent compound **B** was less polar than compound **A** in the  $\alpha^3\beta$ -conformer. In summary (Scheme 2), (i) compound **A** is porphyrin **2** in the  $\alpha^3\beta$ -conformer, (ii) compound **B** is a mixture of **2'** ( $\alpha,\beta,\alpha,\beta$ -conformer) and **2''** ( $\alpha,\alpha,\beta,\beta$ -conformer). Our attempts to perform the same NOE experiment on **3a** unfortunately failed because it was difficult to saturate only the peak of the 1-methyl group at the bottom of cyclohexane ring. The coupling reaction of **2** with 1-methylcyclohexanoyl chloride gave the desired **3a** (yield: 53%).

After detritylation under acidic conditions, 6-(2-methylimidazole-1-yl)hexanoic acid chloride was reacted with the  $\beta$ -*o*-NH<sub>2</sub> group of **4**. Iron insertions of these free base porphyrins were performed with an excess of FeBr<sub>2</sub> with 2,6-lutidine as the base. The total yields of **6a** and **6b** were 15 and 10% from the atrop-isomeric mixture of TAPP. All these compounds are now available in gram quantities.

During the synthesis of the tailed porphyrinatoiron, we are always careful to prevent the atrop isomerizations of the products. The bulky pivalamide or 1-methylcyclohexanamide substituted phenyl rings did not rotate with respect to the porphyrin plane by the ambient light and heating even at 100 °C in toluene for 2 h (*8*). However, the same heating of the detritylated porphyrin **4** afforded two components, the unchanged original **4** and the new one with a lower *R<sub>f</sub>* value. They both showed identical molecular weights. The newly appearing compound is suspected to be the porphyrin **4'** in the  $\alpha^4$ -conformer. Tritylation of **4'** again by the same procedure for TAPP with tritylbromide did not proceed at all due to the steric hindrance of the fence groups next to the NH<sub>2</sub> group.

Table 1. Absorption Maxima ( $\lambda_{\max}$ ) of Tailed Porphyrinatoiron(II) in Toluene

	$\lambda_{\max}$		
	under N <sub>2</sub>	under O <sub>2</sub>	under CO
<b>6a</b>	438, 535, 558	426, 550	424, 535
<b>6b</b>	435, 535, 555	422, 546	421, 534
<b>1a</b>	441, 539, 558	424, 552	425, 534
<b>1b<sup>a</sup></b>	439, 535, 561	422, 550	422, 534

<sup>a</sup> Reference 10b.


Table 2. O<sub>2</sub>-Binding Parameters of Tailed Porphyrinatoiron(II) in Toluene at 25 °C

	<i>k<sub>on</sub></i> (M <sup>-1</sup> s <sup>-1</sup> )	<i>k<sub>off</sub></i> (s <sup>-1</sup> )	<i>P</i> <sub>1/2</sub> (Torr)
<b>6a</b>	$5.8 \times 10^7$	$5.1 \times 10^4$	67
<b>6b</b>	$8.6 \times 10^7$	$5.6 \times 10^4$	50
<b>1a<sup>a</sup></b>	$1.8 \times 10^8$	$4.7 \times 10^4$	20
<b>1b<sup>a</sup></b>	$1.6 \times 10^8$	$7.9 \times 10^4$	38

<sup>a</sup> Reference 2.

**O<sub>2</sub>-Binding Properties of Tailed Porphyrinatoiron(II) in Toluene Solution.** UV–Vis absorption spectra of ferrous **6a** and **6b** in toluene solution under an N<sub>2</sub> atmosphere were very similar to those of the five-N-coordinate complexes of **1a** and **1b** (Table 1). This indicates that **6a** and **6b** are also five-N-coordinate high-spin Fe<sup>2+</sup> complex with an intramolecularly coordinated imidazole tail. Upon bubbling of O<sub>2</sub> gas into these solutions, the absorption spectra immediately changed to that of the well-characterized O<sub>2</sub> adduct complex of the Fe<sup>2+</sup>TPP derivative. After passing the CO gas, the spectral pattern was converted to the typical carbonyl complex. There is no significant difference in the  $\lambda_{\max}$  values of **6a**, **6b**, **1a**, and **1b** within 6 nm.

The binding affinities (*P*<sub>1/2</sub>), association and dissociation rate constants (*k<sub>on</sub>*, *k<sub>off</sub>*) of O<sub>2</sub> to the tailed porphyrinatoiron(II)s, **6a** and **6b**, were determined (Table 2). We thought that the reduction of the fence numbers on the porphyrin ring plane from four to three unfastens the steric hindrance around the O<sub>2</sub>-coordination site and enhanced the association rate constant of O<sub>2</sub>. It is generally recognized that the *k<sub>on</sub>* value increases with the relaxing distal steric encumbrance (*1*, *11*, *12*, *15*). However, the reverse was the case. In contrast to our assumption, the *k<sub>on</sub>* values of the tailed porphyrinatoirons, **6a** and **6b**, were 3.1- and 1.9-fold lower than the corresponding  $\alpha^4$ -conformers (**1a** and **1b**), respectively, while their *k<sub>off</sub>* values were nearly the same. This result suggests that the steric hindrances for the O<sub>2</sub> association to **6a** and **6b** are greater than those of **1a** and **1b**. Most probably, three fences on the amide bonds in the  $\alpha^3\beta$ -



**Figure 2.** UV-Vis absorption spectral change of HSA-6a hybrid in phosphate buffered solution (pH 7.3).

**Table 3.** Absorption Maxima ( $\lambda_{\max}$ ) of HSA-Tailed Porphyrinatoiron (II) Hybrid in Phosphate Buffered Solution (pH 7.3)


	$\lambda_{\max}$		
	under N <sub>2</sub>	under O <sub>2</sub>	under CO
HSA-6a	440, 536, 559	427, 550	427, 539
HSA-6b	—	—	424, 537
HSA-1a <sup>a</sup>	445, 543, 567	428, 555	429, 545
HSA-1b <sup>a</sup>	443, 542, 567	426, 552	427, 539

<sup>a</sup> Reference 2.

conformer can easily move on the porphyrin platform compared to the crowded four fences of the  $\alpha^4$ -conformer. These flexible geometries of the substituents, if anything, narrowed the encumbrance around the O<sub>2</sub>-coordination site relative to the  $\alpha^4$  arrangement.

**O<sub>2</sub>-Binding Properties of HSA-Tailed Porphyrinatoiron in Aqueous Medium.** The tailed porphyrinatoirons, **6a** and **6b**, in the  $\alpha^3\beta$ -conformer could be incorporated into hydrophobic domains of HSA, providing the corresponding albumin-heme hybrids. Their maximum binding numbers to HSA were determined to be approximately 8 (mol/mol), which is identical to those of **1a** and **1b** (2, 10a). It is known that HSA binds porphyrin derivatives and their binding sites largely depend on the chemical structures, hydrophobicity, and electrostaticity. Crystal structure analysis of HSA complexed with natural Fe<sup>3+</sup> protoporphyrin IX, namely, hemin, revealed that hemin is accommodated into subdomain IB of HSA (17). On the other hand, hematoporphyrin is incorporated into subdomain IIIA (18), and tetrakis(*p*-sulfonatophenyl)porphyrin binds to subdomain IIA or IIIA (19). On the basis of the competitive binding inhibition, we supposed that the some of the binding sites of **1a** are subdomains IB, IIA, and IIIB (10a). Attempts to crystallize HSA-6a hybrid are now underway, but the porphyrin **6a** dissociated from albumin during the crystallization process due to the relatively low binding constants of **6a** to HSA ( $10^6$ – $10^4$  M<sup>-1</sup>) and coexistence of poly(ethylene glycol) in the media. We suspect that the binding sites of **6a** and **6b** are the same places of **1a**. The isoelectric point (*pI* = 4.8) and circular dichroism spectral patterns of HSA-6a and HSA-6b were similar to those of HSA itself, indicating that the surface and conformation of albumin were unaltered after bindings of the tailed porphyrinatoirons.

UV-Vis absorption spectra of the freshly prepared ferrous HSA-6a showed  $\lambda_{\max}$  values at 424 and 537 nm (Figure 2, Table 3). This spectrum was almost identical to that of the CO coordinated low-spin **6a** in toluene solution, implying that the incorporated tailed porphyrinatoiron(II) is still the CO adduct complex in HSA. Light irradiation to this aqueous HSA-6a using a 500-W halogen lamp under an O<sub>2</sub> atmosphere leads to



**Figure 3.** MCD spectral changes of (a) HSA-6a and (b) HSA-1a hybrids in phosphate buffered solution (pH 7.3). Solid line: under O<sub>2</sub>; dotted line: under N<sub>2</sub>; dashed line: under CO.

**Table 4.** O<sub>2</sub>-Binding Parameters of HSA-Tailed Porphyrinatoiron (II) Hybrid in Phosphate Buffered Solution (pH 7.3) at 25°C

	$k_{\text{on}}$ (M <sup>-1</sup> s <sup>-1</sup> )		$k_{\text{off}}$ (s <sup>-1</sup> )		$P_{1/2}$ (Torr) <sup>a</sup>
	fast	slow	fast	slow	
HSA-6a	$2.9 \times 10^7$	$4.4 \times 10^6$	$1.1 \times 10^3$	$1.6 \times 10^2$	22 (45) <sup>b</sup>
HSA-1a <sup>c</sup>	$4.6 \times 10^7$	$7.3 \times 10^6$	$9.8 \times 10^2$	$1.6 \times 10^2$	13 (35) <sup>b</sup>


<sup>a</sup>  $P_{1/2} = (k_{\text{on}}/k_{\text{off}})^{-1}$ . <sup>b</sup> At 37 °C in parentheses. <sup>c</sup> Reference 2.

CO dissociation, giving a typical spectral pattern of the O<sub>2</sub> adduct complex. Upon exposure of the dioxygenated HSA-6a to N<sub>2</sub>, the absorption spectrum changed to that of the five-N-coordinated ferrous complex with an intramolecularly coordinated axial imidazole. This O<sub>2</sub> binding and releasing were found to be reversible.

In contrast, the ferrous HSA-6b was irreversibly oxidized during the CO dissociation process under an O<sub>2</sub> atmosphere. We concluded that the bulky and hydrophobic substituent like the 1-methylcyclohexanamide fences are necessary for the tailed porphyrinatoiron(II) in the  $\alpha^3\beta$ -conformer to form a stable O<sub>2</sub> adduct complex under physiological conditions (pH 7.3, 37 °C).

The magnetic circular dichroism (MCD) spectra of HSA-6a showed almost the same pattern as those of HSA-1b (Figure 3) (20). Under an N<sub>2</sub> atmosphere, the MCD spectrum of HSA-6a showed the formation of the five-coordinate ferrous high-spin complex of **6a** with the intramolecular coordinated proximal imidazole. This result showed no ligation of the amino acid residues of the protein, e.g., histidine, tyrosine, cysteine, to the sixth coordination site of the heme. The bulky fences on the porphyrin plane could prevent access of the neighboring peptide residues to the sixth coordination site of **6a**. Upon exposure of this solution to O<sub>2</sub>, the spectrum immediately changed and showed an S-shaped A-term MCD in the Soret region, which indicates a transformation to the ferrous low-spin complex (8, 21). The CO adduct complex of HSA-6a also exhibited a similar A-term MCD band in the same region with a much stronger intensity. The wavelength where the value of  $[\theta]_M$  is zero for the O<sub>2</sub> and CO adduct complex coincided well with the absorption maxima in their corresponding UV-Vis spectra.

The  $P_{1/2}$  of the HSA-6a was determined by measuring the UV-Vis absorption spectral changes during the O<sub>2</sub> titration. The laser flash photolysis experiments provided the  $k_{\text{on}}$  and  $k_{\text{off}}$  values of the O<sub>2</sub> binding to HSA-6a (Table 4). The absorption decays accompanying the O<sub>2</sub> recombination were composed of two-phases of the first-order kinetics. The curve was fitted by



**Figure 4.** O<sub>2</sub>-binding equilibrium curve of HSA-6a under physiological conditions (pH 7.3, 37 °C).

a double exponential equation, which was assigned to the fast and slow rebindings [ $k_{on}(\text{fast})$  and  $k_{on}(\text{slow})$ ] of O<sub>2</sub>. The  $k_{on}(\text{fast})$  values were 7 times greater than  $k_{on}(\text{slow})$ , and the concentration ratio of the fast and slow reactions was 2:1. This is presumably because the O<sub>2</sub> association to **6a** in HSA is influenced by the molecular microenvironment in the hydrophobic domains (steric hindrance of the amino acid residue and difference in polarity). This behavior was similarly observed in HSA-1a and HSA-1b (2, 22). The  $k_{on}$  values of HSA-6a are again 1.6–1.7-fold lower than those of HSA-1a in aqueous medium as observed in toluene solution. This is also caused by the narrow encumbrance on the porphyrin ring plane constructed by the three 1-methylcyclohexanamide fences of **6a**.

The HSA-6a did not show a cooperative O<sub>2</sub>-binding profile like Hb; the Hill coefficient was 1.0 (Figure 4). Although the O<sub>2</sub>-binding affinity of HSA-6a at 37 °C is relatively low ( $P_{1/2}$  value (45 Torr) is high) compared to those of HSA-1a (35 Torr) and human red blood cells (28 Torr), the O<sub>2</sub>-transporting efficiency of HSA-6a between the lungs ( $P_{O_2}$ : 110 Torr) and muscle tissues ( $P_{O_2}$ : 40 Torr) is estimated to be 22%, which is identical to human red blood cells and HSA-1a.

## CONCLUSIONS

Tailed porphyrinatoirons have been first employed as an O<sub>2</sub>-binding site of the synthetic hemoprotein, albumin-heme. **6a** and **6b** with a  $\beta$ -*o*-(2-methylimidazolyl)hexylamide tail have been easily synthesized via four steps from the TAPP scaffold compared to the eight steps of **1a**. The stereochemistry of the  $\alpha^3\beta$ -conformer was confirmed by NOE experiments. The association rates of O<sub>2</sub> were slower than for the corresponding  $\alpha^4$ -conformers, which indicates that three substituents are close to the porphyrin platform and narrowed the encumbrance space around the O<sub>2</sub>-coordination site. As an active site for the albumin-heme hybrid, **6a** was effective, but **6b** was rapidly oxidized. It can be concluded that bulky and hydrophobic substituents like the 1-methylcyclohexanamide fences are necessary for obtaining a stable O<sub>2</sub> adduct complex. The O<sub>2</sub> transporting ability of the HSA-6a was almost the same as human red blood cells. Currently, since HSA is manufactured on a large scale by yeast expression (23), the 5 wt % albumin-heme solution involving **6a** as O<sub>2</sub> binding site is the most promising material as a red blood cell substitute and O<sub>2</sub>-carrying therapeutic reagent, which would be mass produced on an industrial scale.

## ACKNOWLEDGMENT

This work was partially supported by Grant-in-Aid for Scientific Research (No. 16350093) from JSPS, Grant-in-Aid for Exploratory Research (No. 16655049) from MEXT Japan, and Health Science Research Grants (Regulatory Science) from MHLW Japan.

**Supporting Information Available:** Synthetic procedure of the tailed porphyrinatoirons (**6a**, **6b**); <sup>1</sup>H NMR and NOE differential spectra of compounds **A1**, **B1**, and **B2**. These materials are available free of charge via the Internet at <http://pubs.acs.org>.

## LITERATURE CITED

- (1) (a) Collman, J. P., Boulatov, R., Sunderland, C. J., and Fu, L. (2004) Functional analogues of cytochrome *c* oxidase, myoglobin, and hemoglobin. *Chem. Rev.* 104, 561–588. (b) Mometeau, M., and Reed, C. A. (1994) Synthetic heme-dioxygen complexes. *Chem. Rev.* 94, 659–698 and references therein.
- (2) Komatsu, T., Matsukawa, Y., and Tsuchida E. (2002) Effect of heme structure on O<sub>2</sub>-binding properties of human serum albumin-heme hybrids: Intramolecular histidine coordination provides a stable O<sub>2</sub>-adduct complex. *Bioconjugate Chem.* 13, 397–402.
- (3) Komatsu, T., Moritake, M., Nakagawa, A., and Tsuchida, E. (2002) Self-organized lipid-porphyrin bilayer membranes in vesicular form: Nanostructure, photophysical properties and dioxygen coordination. *Chem. Eur. J.* 8, 5469–5480.
- (4) Komatsu, T., Oguro, Y., Teramura, Y., Takeoka, S., Okai, J., Anraku, M., Otagiri, M., and Tsuchida, E. (2004) Physicochemical characterization of cross-linked human serum albumin dimer and its synthetic heme hybrid as an oxygen carrier. *Biochim. Biophys. Acta* 1675, 21–31.
- (5) (a) Huang, Y., Komatsu, T., Yamamoto, H., Horinouchi, H., Kobayashi, K., and Tsuchida, E. (2004) Safety evaluation of an artificial O<sub>2</sub> carrier as a red blood cell substitute by blood biochemical tests and histopathology observations. *ASAIO J.* 50, 525–529. (b) Komatsu, T., Huang, Y., Yamamoto, H., Horinouchi, H., Kobayashi, K., and Tsuchida, E. (2004) Exchange transfusion with synthetic oxygen-carrying plasma protein “albumin-heme” into an acute anemia rat model after seventy-percent hemodilution. *J. Biomed. Mater. Res.* 71A, 644–651. (c) Huang, Y., Komatsu, T., Yamamoto, H., Horinouchi, H., Kobayashi, K., and Tsuchida, E. (2004) Exchange transfusion with entirely synthetic red-cell substitute albumin-heme into rats: physiological responses and blood biochemical tests. *J. Biomed. Mater. Res.* 71A, 63–69.
- (6) Kobayashi, K., Komatsu, T., Iwamaru, A., Matsukawa, Y., Horinouchi, H., Watanabe, M., and Tsuchida, E. (2002) Oxygenation of hypoxic region in solid tumor by administration of human serum albumin incorporating synthetic hemes. *J. Biomed. Mater. Res.* 64A, 48–51.
- (7) Lindsey, J. (1980) Increased yield of a desired isomer by equilibriums displacement on binding to silica gel, applied to meso-tetrakis(*o*-aminophenyl)porphyrin. *J. Org. Chem.* 45, 5215–5215.
- (8) Collman, J. P., Brauman, J. I., Doxsee, K. M., Halbert, T. R., Bunnenberg, E., Linder, R. E., LaMar, G. N., Gaudio, J. D., Lang, G., and Spartalian, K. (1980) Synthesis and characterization of “tailed picket fence” porphyrins. *J. Am. Chem. Soc.* 102, 4182–4192.
- (9) Tsuchida, E., Hasegawa, E., Komatsu, T., Nakata, T., Nakao, K., and Nishide, H. (1991) Synthesis and coordination behaviors of new double-sided porphyrinatoiron(II) complexes: effect of the pocket size for imidazole on dioxygen binding. *Bull. Chem. Soc. Jpn.* 64, 888–894.
- (10) (a) Komatsu, T., Hamamatsu, K., Wu, J., and Tsuchida, E. (1999) Physicochemical properties and O<sub>2</sub>-coordination structure of human serum albumin incorporating tetrakis(*o*-pivalamido)phenylporphyrinatoiron(II) derivatives. *Bioconjugate Chem.* 10, 82–86. (b) Tsuchida, E., Komatsu, T., Kumamoto, S., Ando, K., and Nishide, H. (1995) Synthesis and O<sub>2</sub>-binding properties of tetraphenylporphyrinatoiron(II) derivatives bearing a proximal imidazole covalently bound at the  $\beta$ -pyrrolic position. *J. Chem. Soc., Perkin Trans.* 2, 747–753.
- (11) Collman, J. P., Brauman, J. I., Iverson, B. L., Sessler, J. L., Morris, R. M., and Gibson, Q. H. (1983) O<sub>2</sub> and CO binding to iron(II) porphyrins: A comparison of the “picket fence” and “pocket” porphyrins. *J. Am. Chem. Soc.* 105, 3052–3064.
- (12) Traylor, T. G., Tsuchiya, S., Campbell, D., Mitchell, M., Stynes, D., and Koga, N. (1985) Anthracene heme cyclophanes. Steric Effects in CO, O<sub>2</sub> and RNC Binding. *J. Am. Chem. Soc.* 107, 604–614.
- (13) Collman, J. P., Broring, M., Fu, L., Rapta, M., Schwenninger, R., and Straumanis, A. (1998) Novel protecting strategy for the synthesis of porphyrins with different distal and proximal superstructures. *J. Org. Chem.* 63, 8082–8083.